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1. Introduction 
 
After the publication of genomes1-5 of many organisms6, including humans3, the next 
collective challenge is to assign and understand the functions of the final genome 
products- proteins. The Structural Biology Roadmap is an effort to create a ‘picture’ 
gallery of the molecular shapes of proteins in the body. These three-dimensional insights 
are crucial for an understanding of basic life-processes, such as the reaction mechanism of 
a drug-converting enzyme, signal transduction from one protein to another, activation of a 
metabolic pathway by a gene effector, or the consequences of mutation on the function of 
an enzyme. 
 
1.1 Calcium Signalling 
 
Calcium (Ca2+) is a ubiquitous intracellular signal responsible for controlling 
numerous cellular processes7, 8. Despite tremendous diversities in their expression, cellular 
activities in virtually all cell types are regulated by common intracellular signalling 
systems. Calcium is one important ubiquitous intracellular messenger, controlling a 
diverse range of cellular processes such as gene transcription, muscle contraction, cell 
proliferation9-15. At one level, its action is simple: cells at rest have a Ca2+ concentration of 
100 nM16 but are activated when this level rises to roughly 1000 nM17. 
An important challenge is to understand how this regulation of Ca2+ can regulate so 
many divergent cellular processes. This is possible due to the versatility of calcium 
signalling mechanism in terms of speed, amplitude and spatio-temporal patterning18-19. 
The versatility emerges from the use of an extensive molecular repertoire of signalling 
components which comprise a Ca2+-signalling toolkit20 that can be assembled in 
combinations to create signals with widely different spatial and temporal profiles. More 
variations are achieved through the interactions (crosstalk) that Ca2+ makes with other 
signalling pathways. This versatility is exploited to regulate various cellular processes. 
The calcium signalling network can be divided into four functional units21: 
 Signalling is triggered by a stimulus that generates various Ca2+-mobilizing 
signals. 
 The latter activates the ON mechanisms that feed Ca2+ into the cytoplasm. 
 Ca2+ serves as a messenger to stimulate numerous Ca2-sensitive processes. 
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 Finally, the OFF mechanisms composed of pumps and exchangers, remove 
Ca2+ from the cytoplasm to restore the resting state. 
 
 
                        
       
 
Figure 1: The four units of Ca2+ signalling network. Stimuli act by generating Ca2+ 
mobilising signals that act on various ON mechanisms to trigger an increase in 
intracellular concentration of Ca2+. The increased level of Ca2+ stimulates various Ca2+-
sensitive processes to trigger many different cellular pathways. The response is terminated 
by OFF mechanisms that restore Ca2+ to its resting level (Ref21). 
 
 
 
The functional relationship between these units is illustrated in the figure below which 
reveals that the signalling network is composed of many components (the Ca2+-signalling 
toolkit). Because many of the molecular components of the toolkit have several isoforms 
with subtly different properties, each cell type can exploit this large repertoire to construct 
versatile Ca2+-signalling networks22. 
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Figure 2: Elements of the Ca2+-signalling toolkit : Cells have an extensive signalling 
toolkit that can be mixed and matched to create Ca2+ signals of widely different properties. 
(Ref. 21) 
 
Each cell type expresses a unique set of components from the Ca2+-signalling toolkit 
to create Ca2+ dependent signalling systems with different spatial and temporal 
properties23. Almost all Ca2+ signalling systems have one thing in common: they function 
by generating brief pulses of Ca2+ 24, 25. These Ca2+ transients are created by variations of 
the basic ON/OFF reactions outlined in Fig.1. 
Signal Ca2+ is derived either from internal stores or from external medium. In case of 
the latter, there are many different membrane channels defined by the way in which they 
are activated, like Voltage Operated Channels26, Receptor Operated Channels27, Store 
Operated Channels28, 29. The release of Ca2+ from the internal stores-mostly the 
endoplasmic reticulum (ER) or its muscle equivalent sarcoplasmic reticulum (SR)30-32 is 
controlled by Ca2+ itself, or by a group of messengers such as innositol-l,4,5-triphosphate, 
cyclic ADP ribose, etc. 
During the ON reaction, Ca2+ flows into the cell and interacts with different calcium 
binding proteins (CaBPs) to initiate cellular responses. CaBPs can be divided into two 
types on the basis of their functions: Ca2+ buffers and Ca2+ sensors33. The buffers which 
become loaded with Ca2+ during the ON reaction and unload during the off-reaction 
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function to fine-tune the spatial and temporal properties of Ca2+ signals34. Calbindin, 
calretinin, parvalbumin are examples of Ca2+ buffers13. Of the Ca2+ which enters the 
cytosol, only a very small proportion ends up being free, because most of it is rapidly 
bound to the buffers, and to a lesser extent to the sensors35. The later respond to an 
increase in Ca2+ by activating diverse processes. Typical examples of calcium sensors are 
troponin C, calmodulin, S100 proteins which have EF-hands that bind Ca2+ and undergo 
large conformational change to activate various downstream effectors36-38. 
The versatility of Ca2+ signalling is greatly enhanced by some of the Ca2+-sensitive 
processes linking to other signalling pathways. The ability of Ca2+ to recruit the 
components of other signalling pathways (for example cyclic AMP and mitogen activated 
protein kinase pathways) 39, 40 is particularly evident in the control of gene transcription. 
Once Ca2+ has carried out its signalling functions, it is rapidly removed from the 
cytoplasm by various pumps and exchangers. The plasma membrane Ca2+ ATPase pumps 
and Na+/ Ca2+ exchangers extrude Ca2+ to the outside whereas the sarco-endoplasmic 
reticulum ATPase pumps return Ca2+ to the internal stores41. The mitochondrion is another 
important component of the OFF mechanism in that it sequesters Ca2+ rapidly during the 
development of Ca2+ signal and then releases it back slowly during the recovery phase. 
 
 
  
                                        Figure 3: Ca2+ signalling in the cell 
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1.2 EF-hand Proteins 
The EF-hand Ca2+ binding motif plays an essential role in eukaryotic cellular signalling, 
and the proteins containing this motif constitute a large and functionally diverse family, 
known as the EF-hand protein superfamily42. It is one of the most successful metal binding 
domains in the whole proteome, with more than seven thousand EF-hand proteins43 
annotated in the genome. Named after a Ca2+ binding motif first seen to be formed by 
helices E and F in the crystal structure of parvalbumin44, the EF-hand is composed of a 
typical helix-loop-helix structural unit: two α helices bridged by a Ca2+ chelation loop. 
                                    
                                            
                                   Figure 4: EF hand motif in calcium binding proteins                    
                                                                                             
The identity of the ligands is semi-conserved in the most common (the ‘canonical’) EF-
hand. However, several non-canonical EF-hands exist that bind Ca2+ by a different 
coordination mechanism45. EF-hands tend to occur in pairs which form a discrete domain 
so that most family members have two, four or six EF-hands46. The canonical EF-hand 
motif is characterised by a sequence of two helices of about 10 amino acids interrupted by 
a 12-residue loop that contains mainly polar and acidic residues where Ca2+ can be 
coordinated47. The conformational effects of Ca2+ binding are varied, function-dependent, 
and in some cases minimal, but can lead to the creation of a protein-target interaction site. 
The Ca2+ binding affinities of EF-hands vary substantially (Kd = 10-4-10-9 M) and are 
amino-acid sequence dependent48, especially with regard to the 12-residue consensus loop 
sequence that provides the ligands of the Ca2+ ion. 
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1.3 S100 Proteins 
 
1.3.1 General Overview 
The S100 proteins (soluble in 100 % ammonium sulphate at neutral pH) 49-50, with 25 
members constitute the largest subgroup of EF-hand proteins. They are small (10-12kD), 
acidic proteins found exclusively in vertebrates51. These proteins are characterised by a 
high degree of conservation in amino acid sequence (25-65%) 52, 3-D structure53 and 
genomic structure54-55. S100 proteins occur extra- and intra- cellularly exhibiting a cell and 
tissue-specific expression. They have no enzymatic activity of their own and exert their 
intracellular effects by interacting with and modulating the activities of other proteins, 
referred to as target proteins. Alteration of S100 functions have been implicated in a large 
number of diseases including cancer, Downe’s syndrome, Alzheimer’s disease, 
cardiomyopathy, psoriasis, cystic fibrosis, amyotrophic lateral sclerosis56-61. Thus S100 
proteins may be important diagnostic markers as well as therapeutic targets for many 
diseases.  
Most S100 genes are located in a cluster in human chromosome 1q2162, 63, which is 
structurally conserved during evolution64. Within this chromosomal region, several 
rearrangements occur during tumour development65. This might be linked to a 
deregulation of S100 gene expression in various tumour types and is associated with 
metastasis and tumour development. 
Another unique feature is that individual members of S100 proteins are localised in 
specific cellular compartments from which some of them are able to relocate upon Ca2+ 
activation66-69, transducing the Ca2+ signal in a temporal and spatial manner, interacting 
with different targets specific for each S100 protein. Furthermore, some S100 proteins are 
even secreted from cells to exert cytokine- and chemokine-like extracellular activities. The 
individual members of S100 family seem to utilise distinct pathways (ER-Golgi route, 
tubulin or actin associated) for their secretion into the extracellular space70.  
 
1.3.2 Structural Overview 
S100 proteins are found as non-covalent homodimers, heterodimers or oligomers, 
with the exception of S100G (calbindin) which is monomeric71. Each S100 monomer is 
characterised by the presence of two Ca2+ binding motifs of the EF-hand type 
interconnected by an intermediate region often referred to as the hinge region. In each 
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Ca2+ binding motif of the EF-hand type, a Ca2+ binding loop is flanked by two α-helices, 
resulting in a helix-loop-helix arrangement72. 
 
 
 
            
 
Figure 5: Schematic representation of the secondary structure of an S100 protein. Each 
Ca2+ binding loop (L1 and L2 in the N-and C-terminal half respectively) is flanked by α-
helices (helices I and II and helices III and IV, for L1 and L2 respectively). A linker 
region, (hinge region, H) connects helix II-III. Helix IV is followed by a C-terminal 
extension. The hinge region and C-terminal extension display the least amount of 
homology among different members of the S100 family.  
 
In case of S100 proteins, the first Ca2+ binding loop (EF1) is unconventional, in that 
it is longer (14 amino acids)73 and rearranged where as the second Ca2+ binding loop is 
canonical (12 amino acids). Hence the two Ca2+ binding sites in a S100 protein bind Ca2+ 
with different affinities, EF1 or the pseudo EF hand having a lower affinity (KD = 200-500 
µM) than EF2 (KD = 20-50 µM)74. Some S100 members also bind Zn2+ and Cu2+. EF2 is 
followed by a C-terminal extension. The highest sequence identity among S100 members 
is found in the Ca2+ binding sites. The hinge region and the C-terminal extension exhibit 
the least amount of sequence identity suggesting that these two regions may have a role in 
the specification of biological activity of individual S100 proteins75.  Upon Ca2+ binding 
almost all S100 proteins undergo a conformational change exposing a previously covered 
hydrophobic patch of residues76. There is a large change in the position of helix III upon 
Ca2+ binding. The interhelical angle between helix III and helix IV changes compared to 
the Ca2+ free structure, exposing the residues required for target recognition and binding77. 
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Figure 6: Calcium-dependent conformational changes in S100 proteins: The 3D 
structures of apo-S100A11 and calcium-S100A11 are shown to demonstrate the calcium-
induced conformational change. In the symmetrical dimmer helices of monomer (I-IV) are 
highlighted in different colours, while the monomer (helices I’-IV’) is coloured grey. As 
sensors, the S100 proteins experience a conformational change upon calcium binding (4 
atoms/dimer). The rearrangement of helix III (orange) exposes previously buried residues 
that are essential to target recognition and further biological response. (Ref 77). 
 
 
1.3.3 Functional Overview 
S100 proteins are proposed to have intracellular and extracellular roles. In mature 
tissues, no S100 protein appears to be ubiquitous. Thus, a certain degree of cell specificity 
exists for any S100 member, implying that the relatively large no. of members is simply 
not due to redundancy. Members of this family are not exchangeable, or specific cell types 
need a specific S100 member. However, in some cases S100 proteins share their target 
proteins and, hence, regulate identical activities (possibly in different cell types). For eg., 
S100A1, S100A2, S100A4, S100B interact with the tumour suppressor p53 but in 
different ways78-81. In still other cases different S100 members take part in regulation of 
similar groups of activities. The intracellular roles of S100 proteins include regulation of 
protein phosphorylation82-84, enzyme activity85-88, Ca2+ homeostasis89, cytoskeletal 
components90-92 and transcription factors92-93. Some S100 members like S100A1, A2, A4, 
A12, S100B, S100P are secreted from cells upon stimulation (by a yet unknown 
mechanism), exerting cytokine and chemokine-like extracellular activities, via the 
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Receptor for Advanced Glycation End Products (RAGE). RAGE is a multiligand receptor 
of the immunoglobulin superfamily94. It has one V-type domain, two C-type domains, a 
transmembrane domain and a cytoplasmic tail. RAGE interacts with structurally different 
ligands probably through oligomerisation of the receptor on the cell surface95. Different 
S100 proteins appear to interact with distinct domains of the extracellular portion of 
RAGE to trigger various cellular effects96. RAGE is expressed at low levels in a wide 
range of differentiated adult cells97. It is highly expressed and associated with many 
inflammation-related pathological states such as chronic inflammation, diabetes, cancer, 
neurodegenerative disorders like Alzheimer’s disease and multiple sclerosis98, 99 along 
with S100 proteins. RAGE is a link between inflammatory pathways and pathways 
promoting tumourogenesis and metastasis. Therefore, characterising the role of S100-
mediated RAGE signalling can be broadly applied to a variety of pathological conditions 
and incorporated into a wide array of treatment regimes for these conditions. 
                                           
 
           Figure 7: Schematic representation of extracellular and intracellular roles 
                                                                          of S100 proteins  
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1.4 Receptor for Advanced Glycation End Products 
   
RAGE is a member of the immunoglobulin superfamily of cell surface molecules100, 
101 and shares structural homology with other immunoglobulin like receptors102, 103. 
Although RAGE is not important to life104, it plays important role in certain human 
pathologies including diabetes, Alzheimer’s disease and cancer105. The mature 382 amino 
acid long RAGE is composed of an extracellular part (314 amino acids), a single 
transmembrane spanning helix (27 amino acids) and a short cytosolic domain (41 aa)106. The 
extracellular part of RAGE contains one variable like V-domain (residues 24-127) and two 
constant like C type domains frequently referred to as C1 (132-230) and C2 (239-320) 
domains. RAGE is known to form oligomers at the cell surface107. RAGE possesses two N-
glycosylation sites, one adjacent to the V-domain and another within the V-domain106, 108. 
 
                                                                                        
  
  
  
  
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic representation of RAGE. The extracellular part comprises V, C1 and 
C2 domains. A transmembrane helix connects the extracellular part with the short 
intracellular domain (ID). RAGE ligands interact with the extracellular domains as 
indicated109. 
 
RAGE ligands include structurally unrelated molecules like AGEs, amphoterin, amyloid ß 
peptide, immunoglobulin light chain amyloid fibrils, transthyretin, S100 proteins110-115. 
RAGE is highly expressed during development but its expression level decreases in adult 
tissue except in lung tissue where it is found in high level116. RAGE expression is also 
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augmented by increased levels of ligands in pathological states. RAGE signalling is complex 
and depends on the cell type, the type and concentration of the ligand. Understanding the 
transcriptional regulation of RAGE is important to understand RAGE signalling. Based on 
mRNA splicing, 20 isoforms of RAGE have been identified so far in various tissues and 
cells.  Many of the S100 proteins (A1, A2, A4, A5, A6, A8/A9, A12, S100B, S100P) 
interact with RAGE and trigger RAGE dependent signalling pathways. Activation of 
multiple intracellular signalling molecules including the transcription factor, NF-kB, MAP 
kinases and adhesion molecules are noted following activation of RAGE. S100 proteins use 
different mechanisms for binding to RAGE. For example, S100B is a homotetramer in the 
high Ca2+ extracellular environment and on binding to RAGE mediates dimerisation of the 
receptor117. S100A12, on the other hand, occurs as hexamer and causes RAGE 
tetramerisation118. RAGE signalling is implicated in inflammation and tumour development. 
 
 
1.5 Calmodulin 
 Calmodulin represents the prototypical intracellular Ca2+ sensor containing four Ca2+ 
binding sites in the loops of four canonical EF-hand motifs119. It is highly conserved and 
widely distributed in all members of the animal and plant kingdoms, fungi and protozoa with 
100% amino acid sequence identity among all vertebrates that synchronise cellular 
responses to cell activation, resulting from an elevation of Ca2+ 120-122. 
 CaM is a 149 amino acid protein consisting of two globular domains, each 
containing two EF-hand motifs connected by a central helix. 
 
                                                                  
 
 
   Figure 11: Structure of CaM in the apo and Ca4 forms. Upon binding Ca2+, the central 
helix of CaM connecting the N-and C-terminal domains bends round leading to a 
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conformational change in the overall structure of CaM, and to the exposure of 
hydrophobic residues interacting with target proteins. 
 The pairing of EF-hands enables cooperativity in their binding of Ca2+ ions123. The 
two domains share high overall sequence homology (75%), as well as structural similarity 
in the presence or absence of Ca2+ ions. However, two Ca2+ ions bind with a 10-fold lower 
affinity (Kd = 10-5 M) to the N-domain than to the C-domain (Kd = 10-6 M). This allows 
CaM to sense transient Ca2+ variations in the cytoplasm over a relatively wide 
concentration range. Upon Ca2+ binding, the linker between the two domains bends round 
and CaM assumes a more globular shape ready to wrap around a substrate recognition site. 
At the same time, the two domains undergo conformational changes exposing 
hydrophobic patches that favour target protein interactions124. 
 CaM can bind to its targets in different ways; in the extended mode interaction its 
domains bind with different regions of the target125. Complexes of CaM with proteins 
from the family of bHLH transcription factors reveal another binding mode that leads to 
CaM-induced dimerisation of the target126. 
 The flexibility of CaM structure and the different binding modes are the key features 
that enable CaM to interact with more than hundred different targets, involved in 
numerous cellular processes like cell division, differentiation, transcription, ion transport 
by membrane channels, membrane fusion, and muscle contraction127-129. 
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1.6 Aims and Overview of the Research 
 
Conversion of the biological information carried by an external or internal stimulus 
into a biological function is a result of the concerted action of various toolkits present 
inside the cells. Proteins are often represented as the major components of such toolkits 
and some proteins have dual or multiple roles as communicators and act as hubs between 
these toolkits. Calcium signalling is one of the major cellular events. S100 proteins 
constitute the largest family of calcium-sensing proteins of the EF-hand type and control 
diverse cellular processes through interaction with an array of target proteins. Despite their 
similar amino-acid sequences and 3-D structures, individual family members exhibit 
diverse biophysical/biochemical properties. However, little is known about the molecular 
mechanisms of their action. Calmodulin, the most versatile protein in vertebrates is able to 
modulate a number of biochemical pathways and acts as a hub for the toolkits that 
participate in calcium mediated signalling events. During my PhD I have focussed on the 
cloning, expression, purification and characterisation (structural and functional) of the 
calcium sensing proteins of S100 family and calmodulin. 
The physiological function of a protein is strictly determined by its function. Solution 
NMR is a powerful tool for structure determination and mobility studies of proteins. One 
aspect of my research involves determination of solution structure of the protein S100A5 
and its dynamics studies in apo- and Ca2+-loaded forms. 
S100 proteins have been implicated in the Ca2+ dependent regulation of various 
intracellular activities like protein phosphorylation, cell proliferation, differentiation, 
motility, etc. Some members are released or secreted into the extracellular space, exerting 
cytokine-like activities through interaction with the cell surface receptor, RAGE (receptor 
for advanced glycation end products). S100 mediated RAGE signalling is implicated in 
diabetes, chronic inflammation, tumour progression. Another line of my research was 
based on interaction studies of RAGE with several extracellular S100 proteins- S100A1, 
A2, A4, A5, A12, S100P. Interactions of S100 proteins with different domains of soluble 
RAGE were studied by solution NMR. For structural characterisation of the complex, a 
homology model was obtained for S100P with the VC1 domain of RAGE and the 
interaction surface mapped. The calcium binding sites of S100 proteins were mutated to 
attach a paramagnetic probe to them for structural investigation of the complex. For 
functional characterisation of S100-RAGE complexes, two human cancer cell lines Panc1 
and SW480 which over-express RAGE were treated with different concentrations of 
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recombinant extracellular S100 proteins. The dose-dependent effect of S100 treatment on 
cell proliferation was studied. Our findings suggest that S100 proteins stimulate 
proliferation of these cancerous cell lines by 20-60%, explaining the role of these proteins 
in tumour progression. Competition experiments were performed where Panc-1 cell line 
was treated with S100 proteins in the presence of different domains of soluble RAGE. The 
objective was to find out if treating cells with a S100 protein in presence of the RAGE 
domain with which it interacts prevented it from stimulating cell proliferation. 
 A third line of my research aims at determining the conformational space sampled by 
the two domain flexible CaBP, CaM based on the use of lanthanide ions in both the N-and 
C-terminal domains and collection of pseudocontact shifts (PCS) and residual dipolar 
coupling (RDC) induced by them. The N60D CaM mutant was used to selectively 
substitute the Ca2+ with paramagnetic ions at the N-domain. A paramagnetic probe was 
introduced in the C-domain of a CaM mutant (with two cysteines) through a lanthanide 
binding tag. The pcs and rdc values calculated for the moving domain with respect to the 
fixed (lanthanide-bearing) domain were used to analyse the interdomain conformational 
variability. The CaM conformations with largest MO (maximum occurrence) were 
calculated using these restraints. MO strategy is based on determining the maximum 
weight that a given conformation can have in any conformational ensemble in agreement 
with all available experimental data. The MO of each conformation decreases towards 
actual probability when the number of experimental restraints is increased. This project 
aimed to analyse how MO values are affected by restraints provided by paramagnetic ions 
located in both domains of CaM. The uniqueness of this study lies not only in the 
structural information about a protein which samples multiple conformations but is also in 
terms of the approach developed to achieve the results. The same approach should, in 
principle, be applicable to other multidomain proteins, as well as to multiple interaction 
modes between two macromolecular partners. This type of information is particularly 
desirable for a biologically significant protein like calmodulin, which is present in all 
eukaryotes and interacts with hundreds of targets to regulate multiple cellular pathways. 
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2.1 Cloning of S100 proteins 
 
During the period of my PhD, I have cloned the following S100 proteins: S100A1, 
S100A2, S100A4, S100A5, S100A12, S100A14, S100P, S100Z. The cDNAs of all the 
S100 proteins were purchased from Imagenes. S100A1, A2, A5, A12, A14 and Z were 
cloned in the vector pET21a using the classical cloning method (using restriction 
enzymes). S00A4 was cloned in pET DEST 42 and S100P in pETG-30A using Gateway 
technology.  
 
        
                                          Figure 1: Map of pET21a vector 
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 Primer designing  
 The NEB cutter tool was used to find out which restriction enzymes did not cleave 
the gene sequences of S100 proteins. None of the S100 genes contain the recognition site of 
Nde1. With the exception of S100Z, the other S100 genes also lack the Xho1 recognition 
sequence. As such, primers were designed for all S100 proteins (excepting S100Z) with 
Nde1 (CATATG) and Xho1 (CTCGAG) cleavage sites at the 5’ ends of the forward and 
reverse complementary sequences respectively. For S100Z, BamH1 recognition sequence 
was introduced at the 5’ end of the reverse primer. The recognition sequences were preceded 
with a few (4-5) bases for efficient cleavage by the restriction enzymes. A stop codon was 
introduced in the reverse primer after the restriction site to eliminate the C-terminal histidine 
tag in the vector. 
 For S100A4 and S100P which were cloned by gateway technology, the sequence 
CACCATG was introduced at the 5’end of the complementary forward primers. For 
S100A4, two stop codons were introduced at the 5’ end of the complementary reverse 
primer to eliminate the C-terminal histidine tag of the vector. 
 
PCR amplification 
 The gene sequences were amplified from the cDNA clone using Pfx50TM DNA 
polymerase from Invitrogen. It is a fusion enzyme consisting of recombinant DNA 
polymerase from the archaean Thermococcus zilligi fused to an accessory protein. The 
highly thermostable polymerase possesses a proofreading 3’-5’ exonuclease activity, while 
the accessory protein stabilises the primer-template complexes in PCR. Pfx50TM offers 50 
times better fidelity than TAQ DNA polymerase coupled with high specificity and an 
extremely fast elongation rate (15 seconds per kb). In addition, the fusion enzyme has an 
intrinsic hot-start capability for room temperature reaction assembly. It produces blunt end 
PCR products. PCR amplification was performed in a reaction volume of 50µl using 50 ng 
of template DNA. The cycling conditions used are as follows: 
    Initial denaturation at 94°C for 2 mins. 
35 cycles of: 
Denaturation: 94°C for 15 seconds 
Annealing: 60-68°C (Tm of primers minus 2°) for 30 seconds 
Extension: 68°C for 60 seconds 
Final extension: 68°C for 5 minutes 
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  The PCR amplified genes (270-320) base pairs were subsequently purified from the 
template, unreacted primers and enzyme with the PCR purification kit from Invitrogen. In 
other cases, the PCR product was resolved on a 1.6% low melting point (LMP) agarose gel 
using 1X TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA). The band was 
excised from the gel and purified by using the commercial gel extraction kit of Invitrogen. 
 
Generation of Entry Clone 
 For S100A1, A2, A5, A12, A14 and Z the entry clone was generated using the 
CloneJetTM PCR Cloning kit from Fermentas. It is an advanced positive selection system for 
high efficiency cloning of PCR products generated with any thermostable DNA polymerase. 
Any blunt or sticky end DNA fragment can be cloned and the kit is ideal for cloning 
phosphorylated or non-phosphorylated DNA fragments. The kit contains a linearised cloning 
vector pJET1.2/blunt which accepts inserts from 6 bp to 10 kb. The 5’ ends of the vector 
cloning site contain phosphoryl groups. Therefore, phosphorylation of PCR primers is not 
required. 
 
                                      
                                             Figure 2: Map of pJET 1.2 vector 
 
The pJET1.2 vector contains a lethal gene which is disrupted by insertion of a DNA insert 
into the cloning site. The recircularised vector expresses a lethal restriction enzyme after 
transformation and is not propagated. As a result, only recombinant clones containing the 
insert appear on culture plates. The vector is ampicillin resistant. 
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 The blunt end PCR products generated by Pfx50 were added to pJET1.2 in a molar 
ratio of 3:1 in presence of the reaction buffer and T4 DNA ligase and incubated at 22°C for 
30 minutes. 5µl of the reaction mixture was used to transform 50µl of competent DH5α cells 
and plated on agar ampicillin plates and incubated overnight at 37°C. 
 For S100A4 and S100P the entry clones were generated by Topo cloning reaction in 
pENTR/SD/D-TOPO (for native protein) and pENTR/TEV/D-TOPO (for N-terminal fusion 
tags with TEV cleavage sites) respectively, using the directional Topo Cloning kit from 
Invitrogen. 
 
                                                        
                     
                 S100A4                                                             S100P 
              Figure 3: Maps of Gateway entry vectors pENTR/SD/D-TOPO (for native  
              protein) and pENTR/TEV/D-TOPO ( for N-terminal fusion proteins with 
                                                               TEV cleavage site 
 
 
 The blunt-ended PCR products were incubated in the topo cloning reaction mixture 
with the linearised vectors in 2:1 molar ratio for 30 minutes at room temperature for ligation. 
The vectors contain a single strand GTGG overhang on the 5’ end and a blunt end on the 3’ 
end. The four nucleotide overhang invades the double strand DNA of the PCR product and 
anneals to the CACC sequence in the 5’ primer. Topoisomerase then ligates the PCR 
product in the correct orientation. 
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           Figure 4: Schematic representation of Directional TOPO Cloning Reaction 
 
 The pENTR vectors contain kanamycin resistance gene for selection in E.coli. Therefore, 
the ligation mix was transformed into E. coli and spread on kanamycin plates. 
 
Screening for Positive Constructs 
 For each S100 construct, a total of 10 colonies were screened by PCR amplification. 
To verify the correct orientation of the inserts, a mixture of vector specific forward primer 
and insert specific reverse primers were used. The PCR amplificates were checked on 1.6% 
agarose gel. The positive clones were purified and further verified by sequencing reactions. 
 
Generation of Expression Clone 
 After sequencing, one positive construct was chosen for each S100 protein and 
proceeded with to create the expression clone.  
 Preparation of Insert: For all the proteins except S100A4 and S100P (for which 
gateway cloning technology was used), 1µg of the recombinant pJET1.2 plasmids with the 
different S100 genes were digested with the corresponding restriction enzymes whose 
recognition sites were introduced at the ends of the genes during PCR amplification. 
S100A1, A2, A5, A12, A14 were digested with Nde1 and Xho1 while S100Z was digested 
with Nde1 and BamH1. The recombinant plasmids were incubated with Fast Digest 
restriction enzymes from Fermentas for 1 hour at 37°C to excise the digested S100 genes 
from the plasmids. Restriction enzymes were inactivated by treating the reaction mixture at 
80°C for 5 minutes. The entire reaction volume was loaded on a 1.6% agarose gel. The 
digested bands of S100 genes were excised and purified by the gel extraction kit from 
Invitrogen. 
  Preparation of Vector: 1µg of pET 21a was digested with Nde1 and Xho1 (for 
S100A1, A2, A5, A12, A14) or Nde1 and BamH1 (S100Z) by incubating the plasmid with 
Fast Digest restriction enzymes for 1hour at 37°C. The restriction enzyme was heat 
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inactivated at 80°C for 5 minutes. The linearised vector was treated with calf intestinal 
alkaline phosphatase (CIP) for 1 hour at 37°C to dephosphorylate its 5’ends and thereby 
minimise the chances of recircularisation. CIP was heat inactivated at 65°C for 20 minutes. 
The reaction mixture was loaded on a 0.8% gel and the linearised vector was excised and 
purified by gel extraction kit (Invitrogen). 
 Ligation: Ligation was performed using either the Rapid Ligation kit or the T4 DNA 
ligase from Fermentas. The digested insert and vector were mixed in the ratio 0f 3:1. For 
quick ligation, the reaction was incubated at 22°C for 1 hour while for T4 DNA ligase 
incubation was done at 22°C for 2 hours or 4°C overnight. 5µl of the ligation reactions were 
transformed into E. coli DH5α competent cells and spread on ampicillin plates for overnight 
incubation. 
 LR reaction: For S100A4 and S100P, which were cloned in gateway entry vectors, 
the expression clone was generated by transferring the S100 genes in destination vectors by 
the LR reaction. The LR reaction mix containing entry clone and destination vector was 
incubated at 25°C for 60 minutes. To terminate the reaction, proteinase K solution was 
added and the sample was incubated at 37°C for 10 minutes. 
      
                          
                     Figure 5: Schematic Representation of LR Reaction  
 
The S100A4 gene was transferred to the expression vector pET DEST 42 (without fusion 
tags) while S100P was transferred to the vector pETG-30A with a N-terminal GST and 
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hexahistidine tag. 1µl of the reaction was transformed into chemically competent DH5α 
cells, spread on LB ampicillin plates and incubated overnight at 37°C. 
 
                                         
 
Figure 6: pET-DEST 42-destination vector for S100A4 without N-terminal fusion tag; 
pETG-30A-destination vector for S100P with N-terminal GST and histidine tag. 
  
Screening for Positive Constructs 
To screen for the positive colonies, 10 colonies of each S100 protein were analysed by 
colony PCR. To verify the orientation of the insert in the vector, a gene specific forward 
primer and vector specific reverse primer (T7 terminator) was used in the PCR reaction. 
The amplificates were resolved in a 1.6% agarose gel. One of the the positive colonies of 
each protein were chosen for expression tests. 
 
2.2 Expression of S100 proteins 
 The recombinant plasmids carrying different S100 genes were transformed into 
different E. coli expression strains: BL21(DE3), Gold, pLys S, Codon Plus DE3) RIL. 
Protein expression was checked in each of them with 5 ml cultures. The strain with 
optimal expression was chosen for further tests including varying conditions of inducer 
concentration, induction temperature and length of induction. The conditions checked for 
expression are as follows: 
  IPTG concentration: 0.4 mM, 0.5 mM, 0.7 mM, 1.0 mM. 
  Induction temperature: 37°, 30°, 25°, 20°, 17°C. 
  Induction period: Every 1 hour after induction upto 6 hours and overnight  
                    (12-16 hours). 
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For each S100 protein, expression was checked under the above conditions. Samples of 
soluble and insoluble cellular fractions were analysed on 15% SDS-PAGE. The cellular 
fractions which contain the protein and optimal expression conditions were determined for 
large scale protein expression. The optimised expression conditions for all the S100 
proteins have been summarised in the table below. 
 
S100 Protein Plasmid E. coli strain 
IPTG 
Concentration 
Induction 
Temperature 
Induction 
Period 
S100A1 pET21a Gold 1.0 mM 37°C ON 
S100A2 pET21a Gold 0.5 mM 37°C ON 
S100A4 
pET DEST 
42 
pLys S 0.5 mM 25°C ON 
S100A5 pET21a Gold 0.5 mM 25°C ON 
S100A12 pET21a Gold 1.0 mM 37°C ON 
S100P pETG-30A Gold 1.0 mM 25°C ON 
S100A14 pET21a Codon Plus 0.5 mM 37°C ON 
S100Z pET21a Gold 0.5 mM 37°C ON 
 
 
2.3 Purification of S100 proteins 
 Protein purification was based on the intrinsic properties of S100 proteins:  
a) Solubility of S100 proteins in 100% saturated ammonium sulphate solution at neutral 
pH. 
b) Calcium binding to most S100 proteins exposes a patch of hydrophobic residues on the 
protein surface which otherwise remain buried in the apo form. 
 
S100 A1, A2, A5 and A12 was purified as follows: 
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1) Bacterial cells pelleted from the culture were resuspended in lysis buffer 20 mM Tris, 
1mM PMSF, 2 mM DTT, 2 mM DTT, pH 7.5. In case of S100A12, 100 mM NaCl 
was included in the buffer.  
2) Cells were lysed by sonication and the suspension was ultracentrifuged at 40,000 rpm 
for 30 minutes. 
3) S100 proteins were present in the soluble cellular fraction in all cases. So the clarified 
lysate was subjected to purification.  
For S100A5, 30% ammonium sulphate was added to the lysate at 4°C with constant 
stirring to precipitate out impurities. The suspension was kept in stirring condition for 
at least 2 hours to allow it to become homogeneous. After the stipulated period, it was 
centrifuged at 9000 rpm for 20 mins. The pellet of precipitated proteins was discarded 
and the supernatant containing S100A5 was collected for further purification. 
4) To the lysate of A1, A2, A12 and the supernatant from step 3 of A5, 5 mM CaCl2 was 
added to convert the S100 proteins to their holo form and thereby expose the 
hydrophobic amino acids at the surface. S100A12 precipitates out of the lysate when 
CaCl2 is added to it directly. So A12 lysate was diluted with buffer containing CaCl2 in 
the ratio of 1:5. After addition of CaCl2 the suspension was clarified by centrifugation 
in all cases. 
Chromatographic steps: 
a) Hydrophobic Interaction Chromatography: A 5 ml Phenyl Sepharose high sub 
column (from Amersham Biosciences) was equilibrated with lysis buffer containing 
CaCl2. The supernatant from step 4 was loaded on the column at a rate of 0.4-0.5 
ml/min for optimal binding. Unbound proteins were washed out of the column with 
12-15 column volumes of equilibration buffer. The bound S100 proteins were then 
eluted with 20 mM Tris, 10 mM EDTA, pH 7.5. 
                                                         M        L1         L2            L3        L4 
                                    14.4 kD    
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             M: Marker, L1: Lysate, L2: Column flowthrough, L3: Wash, L4: Elution 
Figure 7: Polyacrilamide gel showing fractions of S100 proteins from hydrophobic 
interaction chromatography. 
b) Gel Filtration: The elution from the HIC column was concentrated and loaded on a 
Superdex 75 16/60 column. Proteins were eluted in the final buffer 30 mM MES, 100 
mM NacCl, 5 mM DTT, pH 6.5. 
 
          
                            Figure 8: Chromatogram of gel filtration of S100 protein 
 
                                                  
                                Figure 9: SDS PAGE of gel filtration fractions of S100 protein. 
 
Purification of S100A4 
a) Anion exchange: A HiTrap Q (stong anion exchange) column was equilibrated with 
20 mM Tris, 100 mM NaCl, pH 8.0. The lysate was loaded on the column. S100A4 
was recovered in the unbound fraction. The bound impurities were eluted from the 
column with 20 mM Tris, 1M NaCl, pH 8.0. 
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b) Cation exchange: The column flowthrough of anion exchange was buffer exchanged 
into 20 mM MES, 50 mM NaCl, pH 5.6. It was loaded on a Hi Trap SP (strong cation 
exchange) column equilibrated with the same buffer. Bound S100A4 was eluted with a 
salt gradient from 50-500 mM. The protein eluted at 300 mM salt concentration. 
c) Gel filtration: The purest fractions of cation exchange were concentrated and loaded 
on a Superdex 75 16/60 column. S100A4 was eluted with 30 mM MES, 100 mM 
NaCl, 5 mM DTT, pH 6.5. 
 
Purification and Refolding of S100A14 
S100A14 is expressed in the inclusion bodies of E. coli. The protein was therefore 
extracted from the inclusion body in 20 mM Tris, 1 mM EDTA, 5 mM DTT, 8M urea, pH 
8.0. The unfolded protein was purified by anion exchange using a Q sepharose column. 
S100A14 does not bind to Q column at pH 8. The bound impurities were eluted with the 
same buffer containing 800 mM NaCl. The unbound fractions containing the protein were 
refolded by dialysing it against a deacreasing urea gradient till the urea concentration 
reached zero. The folded protein was further purified by size exclusion chromatography 
and eluted in 30 mM MES, 100 mM NaCl, 5 mM DTT, pH 6.5. 
 
Purification of S100P 
 
S100P was expressed as a fusion protein with N-terminal GST and Histidine tag. As such 
it was purified by immobilised metal ion chromatography (IMAC). The bacterial pellet 
was resuspended in 1X phosphate buffer, 10 mM imidazole, pH 7.4 (binding buffer). Cells 
were lysed by sonication and the suspension ultracentrifuged. The lysate was purified as 
follows: 
a) Lysate was loaded on a nickel sepharose column equilibrated with binding buffer. 
b)  Unbound proteins were washed out with several column volumes of binding buffer.  
c) Impurities bound to the column were washed out with 1X phosphate buffer, 100 mM 
imidazole, pH 7.4. 
d) The bound his-tagged S100P was eluted with 1X phosohate buffer, 500 mM 
imidazole, pH 7.4. 
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Tag cleavage 
 
In pETG-30A a TEV protease recognition site is incorporated between the N-
terminal tag and the recombinant gene. TEV protease is a highly site-specific cysteine 
protease that is found in Tobacco Etch Virus (TEV). The optimum recognition site for this 
enzyme is Glu-Asn-Leu-Tyr-Phe-Gln-(Gly/Ser) and cleavage occurs between the Gln or 
Gly/Ser residues.  For cleaving the tag from S100P the elution from nickel column was 
first changed into TEV buffer (50 mM Tris-HCl , pH 8; 0.5 mM EDTA, 1 mM DTT). The 
fusion protein was incubated overnight with recombinant (histidine–tagged) TEV protease 
at room temperature. 
 
 
Separation of cleaved S100P 
The cleaved S100P was purified from the tag and TEV protease by passing the 
mixture over a nickel column. S100P was collected as column flow through. The bound 
tag and TEV protease were eluted with imidazole. 
 
S100Z has been found to be expressed in the inclusion bodies. Its purification and 
refolding protocols are being optimised. 
 
 
   2.4 Paramagnetic Probe attachment to S100 proteins 
  
 Paramagnetic probes are important tools for studying protein structure and dynamics. 
They can be particularly useful in investigating protein-protein interactions, providing 
long range distance restraints to characterise the complex. To attach a paramagnetic metal 
to S100 proteins, the EF2 of several S100 proteins were mutated to tune their affinity for 
lanthanides and replace the calcium at the binding site with a lanthanide. Mutations were 
based on sequence alignment of the EF2 of these S100 proteins with S100G/calcindin 
D9K, whose EF2 has a strong affinity for lanthanides, so that the calcium at the binding 
site can be preferentially replaced by a paramagnetic metal.  
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* = any residue; X = first calcium ligand; Y = second calcium ligand; Z = third calcium 
ligand; G = glycine; # = fourth calcium ligand, provided by a backbone carbonyl; I = 
isoleucine (although other aliphatic residues are also found at this position); x = fifth 
calcium ligand; z = sixth and seventh calcium ligands, provided by a bidentate glutamate 
or aspartate residue 
Figure 10: Sequence alignment of EF-2 of S100 proteins with that of calbindin (S100G). 
 
The mutations designed were as follows: 
               S100A5: Q65G, K70E 
    S100P   : A67G, Q68E, S72E 
    S100A2: Q69E 
The EF-2 of S100A1 is strikingly similar to that of calbindin (differing in only two 
residues). So this protein was also expressed for paramagnetic studies. 
 
 
Mutagenesis Protocol 
 
The mutations listed above were performed using the Quick Change Site-Directed 
Mutagenesis kit from Stratagene as follows: 
 
Mutagenic Primer Design: Both sense and antisense primers were designed in a way that 
they contained the desired mutation and annealed to the same sequence on opposite 
strands of the template plasmid. Primer lengths were kept typically between 30-35 bases. 
The desired mutation was in the middle of the primer with approximately 10-15 bases of 
correct sequence on both sides. Each primer terminated in G or C bases, had a GC content 
of about 40% and Tm ≥ 78°C. Tm was calculated using the following formula: 
              X*-Y*ZG#Ix**z 
CALB9      :  DK-NGDGEVSFEE                
S100A5     :  DK-NSDQEIDFKE  
S100A1     :  DE-NGDGEVDFQE 
S100P      :  DA-NGDAQVDFSE 
S100A2     :  DE-NSDQEIDFKE 
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Tm = 81.5 + 0.41(%GC) – 675/N - % mismatch 
where N is the primer length in bases, values of %GC and % mismatch are whole 
numbers. 
 
Mutant Strand Synthesis: Recombinant plasmid DNA (containing the wild type gene) 
extracted from DH5α (dam+ strain) was amplified by Pfu Turbo DNA polymerase using 
125 ng of each mutagenic primer. Cycling conditions were determined depending upon the 
type of mutation (point / single amino acid change). 
 
Dpn I digestion of template: Dpn 1 endonuclease is specific for methylated and 
hemimethylated DNA. Parental plasmid DNA was selectively digested leaving the 
synthesised mutated DNA. 
 
Transformation: The amplified mutant DNA was transformed into XL1-Blue 
supercompetent cells and incubated at 37° C for 16-18 hours with suitable antibiotic 
selection. 
The mutations were verified by sequencing reactions. 
The mutants were expressed and purified in the same way as the wild type proteins. 
 
                               
 
 
            Figure 11: Schematic representation of site-directed mutagenesis procedure. 
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2.5 Mammalian Cell Culture and Experimental Design 
 
Cell Culture: The colorectal adenocarcinoma cell line (SW480) and pancreatic carcinoma 
cell line (Panc-1) were obtained from the American Type Culture Collection. Cells were 
grown in high glucose Dublecco’s modified Eagle’s medium (DMEM) supplemented with 
10% foetal bovine serum (FBS), 2 mM glutamine, penicillin (100U/ml), streptomycin 
(100U/ml) and maintained in a humified atmosphere with 5% CO2 at 37°C. 
Cells were cultured for at least two weeks before using them for experiments with regular 
splitting upon reaching confluency. 
RAGE overexpression at the cell surface was verified for both the cell lines with western 
blotting. 
 
Experimental Design 
 For all the experiments cells were seeded in 96-well plates (1x103 cells/well in a volume 
of 100 µl) and incubated for 24 hours to enable them to attach to the extracellular matrix at 
the bottom of the wells. After 24 hours, the medium and unattached cells were removed 
and serum free medium was added to each well (serum may interfere with protein-protein 
interactions and give misleading results). This was followed by recombinant protein 
treatment and incubation for specific time periods. The experiments performed are 
outlined below: 
 
1. Cells were treated with different concentrations (0.1-1-10-100-1000 nM) of 
recombinant S100A1, A2, A4, A5, A12, S100P and incubated for 72 hours. The effect of 
each S100 treatment on cell proliferation was examined. The concentration of each S100 
with maximal effect on cell proliferation was determined for both the cell lines.  
 
2. Cells were treated with the optimal concentration of each S100 protein as determined 
from experiment 1. Proliferation was measured each 24 hour after treatment upto 96 
hours. The growth curves of SW480 and Panc-1 in response to treatment with the optimal 
concentration of each S100 protein were plotted upto 96 hours after treatment.  
 
3. The extracellular part of RAGE consists of 3 domains-V, C1 and C2. Different S100 
proteins bind to separate RAGE domains to activate it. Competition experiments were 
performed where cells were treated with S100 proteins together the three domains of 
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RAGE separately. The effect on cell proliferation for each domain plus S100 was assayed. 
The effect on cell proliferation upon treatment with S100 proteins alone and S100 plus 
RAGE was compared. 
 
Each experimental condition was set up in triplicates to minimise errors. Experiments 
were repeated at least thrice to verify the reliability of results. 
 
Cell proliferation was measured with the CellTiter 96 AQueous One Solution cell 
proliferation assay (MTS; Promega) which is a colorimetric method for determining the 
number of viable cells. The CellTiter 96 AQueous One Solution Reagent contains a 
tetrazolium compound, MTS and an electron coupling regent, PES. PES has enhanced 
stability which allows it to be combined with MTS to form a stable solution. MTS is 
bioreduced by cells into a coloured formazan product that is soluble in tissue culture 
medium. This conversion is accomplished by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active or viable cells. 
For measuring cell proliferation, 20 µl of the reagent was added to each well. The plates 
were incubated for 1.5 – 2 hours at 37°C in humified atmosphere with 5% CO2. 
Absorbance was recorded at 490 nm with a 96-well plate reader. 
 
2.6 Paramagnetic Tag attachment to Calmodulin 
Two residues in the C-terminal domain of CaM, H107C and N111C were mutated to 
cysteines for attachment of the Caged Lanthanide NMR Probe-5 (CLaNP-5) which 
attaches to proteins by two disulphide bonds. 
 
                                      
 
     Figure 12: Caged Lanthanide  
                 NMR Probe-5        
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   The advantages of this probe are: 
A) Due to the presence of two pyridine-N-oxide ligating pendant arms, CLaNP-5 is 
symmetric. 
B) Two-point attachment of CLaNP-5 through disulphide bridges introduces large   
and   well-defined paramagnetic effects by minimising the dynamics of the probe. 
 
Protein Expression and Purification 
The mutant CaM which is cloned in pET 16b has a His (10)-tag separated from the gene 
sequence by a factor Xa cleavage site. The protein was expressed in BL21 DE3 Gold cells 
and purified by a nickel sepharose column followed by tag cleavage. The native protein 
was then purified by a second metal affinity chromatography and gel filtration. For NMR 
experiments, the protein samples were prepared in 30 mM MES, 200 mM KCl, pH 6.8 
Tag attachment Reaction 
For attachment of Ln-CLaNP-5 to H107C/N111C CaM, all operations were performed in 
the glove box.  The 4Ca2+- CaM mutant was reduced by incubating it with 5 mM DTT. 
Calcium was used in excess to avoid the possibility of exchange of calcium ions at the 
binding site with any unchelated lanthanide in the tag solution. DTT was removed under 
reducing conditions. The reduced protein was diluted to 20-30 µM and incubated with 
seven equivalents of Ln-CLaNP-5 in the glove box for 3-4 hrs at room temperature for the 
tag attachment to proceed to completion. . About 1/3 rd of the protein aggregated during 
the tag attachment reaction as observed in non-reducing SDS-PAGE. 
 
 
 
 
 
       
 
 
                                               L1              L2            M 
M: marker (kD)      L1: Tagged CaM (without DTT)      L2: Untagged CaM (without 
DTT). Figure 13:  Non-denaturing polyacrilamide gel showing the aggregation state of 
L2: calcium calmodulin and L1: calcium calmodulin reacted with the Ln-CLaNP-5. 
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The reacted sample was purified by a superdex 200 16/60 column to separate the 
monomer from aggregates. The protein was eluted in 30 mM MES, 200 mM KCl, 20 mM 
CaCl2, pH 6.8.  
 
 
Figure 14: Chromatogram showing elution profile of CaM aggregate and monomer 
from superdex 200 column. 
Tag attachment was verified by comparing the 1H15N-HSQC of the unreacted CaM 
mutant with that of the reacted monomer. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monomer 
 Aggregate 
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           3. Results 
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3.1 Structural characterisation of S100 proteins 
Using the classical cloning method and pET expression system, a significant improvement 
in the expression and yield of S100 proteins were obtained in comparison to the Gateway 
cloning technology. S100 proteins have very low expression when cloned in gateway 
vectors.  Highest expression of these proteins were found when they were cloned in the 
native state, i.e., without any fusion tags.  
To check the folding and quality of the S100 proteins, 15N HSQC of the apo and Ca2+ 
titrated proteins were taken. Following are the HSQC spectra of apo- and holo- S100 
proteins: 
 
             
 
Apo Holo (Ca2+) 
S100A1 
S100A2 
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                                                                       S100P 
 
Figure 1: 1H15N HSQC spectra of apo and holo S100 proteins. 
 
 S100A5 
 S100A12 
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S100A14 which is expressed in the inclusion bodies was refolded and the apo spectrum of 
the protein shows that it is well folded. 
                                                                                                          15N 
 
 
 
 
 
 
 
                                1H 
                                                  Figure 2:  1H15N HSQC spectra of apo S100A14 
The above 15N HSQC spectra were taken at 700 MHz at 298 K. Samples were prepared in 
30 mM MES, 100 mM NaCl, 5 mM DTT, pH6.5. It is evident that all the above S100 
proteins were folded and appropriate for use in NMR experiments. 
                         S100A4 (apo) 
 
Figure 3: 1D spectrum of S100A4. Buffer: 30 mM MES, 100 mM NaCl, 5 mM 
DTT, pH 6.5.   Temp: 298 K.  Spectrum taken at 600 MHz. 
S100A4 was expressed only for cell line studies. Hence only unlabelled sample of this 
protein was prepared.  
One of the aims of this thesis was structural characterisation of S100 proteins. The structure 
of S100A5 was therefore solved by solution NMR. 
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3.2 
 
Solution Structure and Dynamics of S100A5 in the 
apo and Ca2+-bound states 
Bertini I, Das Gupta S, Hu X, Karavelas T, Luchinat C, Parigi G, 
Yuan J.  J Biol Inorg Chem (2009) 14 : 1097-1107. 
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                     3.3 
    
 New insights into the mechanism of RAGE 
    activation by S100 proteins  (in preparation) 
 
 71 
Introduction 
 
 
The Receptor for Advanced Glycation Endproducts (RAGE) is a multiligand receptor that 
interacts with different extracellular ligands (AGEs, amphoterin, -amiloyd peptide, S100 
proteins)1-5 and acts as a sensor for extracellular signals involved in the regulation of cell 
homeostasis and pathological states, including diabetic complications, tumour outgrowth, 
chronic inflammation and neurodegenerative disorders like Alzheimer’s disease or multiple 
sclerosis6-12. RAGE is highly expressed during development13. In adult tissues its expression 
is very low. High expression levels of RAGE are associated with various tumors14, 15, 
including colon adenocarcinoma and pancreatic carcinoma16, 17, where RAGE is involved in 
tumour development and metastasis. 
RAGE is an immunoglobulin-like cell surface receptor18 with an extracellular region 
composed of three immunoglobulin domains (V – C1 – C2), a short transmembrane helix 
and a C- terminal cytosolic tail involved in signal transduction19.   It was originally 
identified and characterized by its ability to bind advanced glycation end products (AGEs). 
Subsequently, a large number of RAGE ligands were identified, including S100 proteins, 
amphoterin/high mobility group box-1, amyloid-, Mac-120. However, the roles of 
individual ligands in the activation of RAGE are not fully understood. 
 This work focuses on studying the interactions between RAGE and S100 proteins. In 
particular we aim to find a key feature in S100 protein-RAGE interactions that can explain 
the differences reported for the RAGE signal transduction pathways induced by different 
members of S100 protein family despite the fact that different S100 proteins share a high 
degree of structural homology.    
The S100 proteins are non-ubiquitous small  acidic proteins (10–12 kDa) belonging to the 
EF-hand calcium-binding family, with 25–65% identity at the amino acid level and are 
found exclusively in vertebrates21, 22, indicating that they are phylogenetically new proteins. 
In human genome, at least 25 members of the S100 proteins are known. Most of these genes 
(S100A1–S100A18, trichohylin, filaggrin and repetin) cluster to chromosome 1q21, 23, 24 
known as the epidermal differentiation complex, which is frequently rearranged in human 
cancer25. Other S100 proteins are found at chromosome loci 4p16 (S100P), 5q14 (S100Z), 
21q22 (S100B) and Xp22 (S100G) 26.  
In vivo and in vitro experiments have shown that the S100 proteins can form non covalent 
homo- and hetero-dimers27 and oligomers28, 29. Besides calcium, some members of the 
family also bind calcium zinc and/or copper30, 31, which triggers structural changes 
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implicated in the interaction with target proteins and in modulation of the oligomaric state, 
contributing to their functional diversity.  
S100 proteins regulate diverse cellular functions both in the intracellular and extracellular 
environments. They are implicated in the regulation of protein phosphorylation32, enzyme 
activities33, dynamics of cytoskeletal components34, transcription factors35, Ca2+ 
homeostasis36, cell proliferation and differentiation37. Some S100 proteins are released into 
the extracellular space by an unknown mechanism. Extracellular S100s can act in a 
cytokine-like manner, as leukocyte chemoattractants, activators for macrophage and other 
inflammatory cells and modulators of cell proliferation38. These functions associate S100 
proteins with a variety of pathologies such as inflammation, cardiomyopathies, and 
carcinogenesis.  Therefore, during the last years, S100 proteins have attracted much 
attention as significant markers for diagnostic and clinical purposes and as therapeutic drug 
targets.  
Many evidences report RAGE as the common receptor for extracellular S100 proteins. A 
large number of S100 proteins interact with RAGE extracellular domains in vitro. In cell-
based assays some S100 proteins trigger RAGE-dependent signalling39, 40, 41. However, the 
molecular mechanism of the interaction is not clearly known, since several factors affect the 
interactions between RAGE and S100 proteins and the pathways triggered thereby. The 
RAGE binding properties of S100 proteins and the cellular effects of RAGE activation are 
modulated by different factors such as the oligomeric state of S100 proteins, their 
extracellular concentrations and metal binding. Moreover post-translational modifications 
such as glycosylation of the receptor or N-(carboxymethyl)lysine (CML) modifications of 
S100 proteins could also play important roles in defining specificity of interactions, 
oligomerization, and signalling. The S100-dependent RAGE activation and the effects on 
cellular activity have been investigated by several authors and summarized by Leclerc et al. 
and Salama et al. (Table 1). However, a standardized cell-based assay and systematic NMR 
analysis are needed to improve the understanding of the RAGE- S100 interactions. 
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Table 1: Summary of S100-protein dependent activation of the RAGE receptor 
 
 
 
In this work the RAGE signal transduction pathways induced by different members of S100 
proteins family has been investigated in vivo and in vitro. A cell-based assay was performed 
to investigate the interaction between seven recombinant S100 proteins and RAGE in two 
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models of human cancer cell lines (SW480 and PANC-1) that express RAGE. The RAGE-
dependent effects of different S100 proteins and the role of extracellular RAGE domains on 
tumour cell proliferation were compared. To further improve the understanding of the 
structural basis of RAGE activation by S100 proteins, the interaction was investigated by 
NMR and a structural model for thye complex of S100P with V domain of RAGE has been 
calculated using HADDOCK program.  
 
Materials and methods 
 
Cell Culture 
The colorectal adenocarcinoma cell line SW480 and the pancreas carcinoma cell line 
PANC-1 were obtained from the American Type Culture Collection (ATCC). Cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (PAA) supplemented with 10% 
foetal bovine serum (FBS) (PAA), 2 mM glutamine (Lonza), penicillin (100U/ml) and 
streptomycin (100 U/ml) (Lonza), and were maintained in a humidified incubator containing 
5%CO2 at 37°C. 
 
Expression and Purification of Recombinant S100 proteins and RAGE domains 
S100 A1, A2, A5, A12 were cloned in pET 21a using the restriction enzymes Nde1 and 
Xho1 in the native form. S100A4 was cloned in pET DEST42. A stop codon was introduced 
at the 3' ends of the gene sequences to eliminate the histidine tag of the vector. S100P was 
cloned in pETG-30A to obtain a fusion protein with N-terminal histidine-GST tag. The 
recombinant plasmids with S100 genes were transformed into Escherichia coli Bl21 (DE3) 
Gold cells except for S100A4 which was expressed in pLys S cells. For protein expression, 
cells were grown at 37°C to an optical density of 0.6 at 600 nm and expression was induced 
with IPTG (0.5-1 mM). After induction, the growth temperature was reduced to 25°C in 
case of S100A4 and S100A5, S100P. Cells were harvested 12-16 hours after induction in all 
cases and resuspended in lysis buffer- 20 mM Tris, 2 mM DTT, 1 mM PMSF, pH 7.5. Lysis 
was performed by sonication. The suspension was ultracentrifuged at 40000 rpm for 30 
minutes. The supernatant was brought to 5 mM CaCl2 and applied to a phenyl sepharose 
(high sub) column equilibrated with 20 mM Tris, 5 mM CaCl2. Loading was done very 
slowly at a rate of 0.4-0.5 ml of lysate/ minute. The unbound proteins were washed out with 
12-15 column volumes of equilibration buffer. S100 proteins were then eluted with 20 mM 
Tris, 10 mM EDTA, pH 7.5. The elute was concentrated and applied to a Superdex 75 16/60 
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column equilibrated with 30 mM MES, 100 mM NaCl, 5 mM DTT (in case of the S100s 
with cysteines), pH 6.5. The purest fractions were pooled and washed with EDTA to obtain 
the protein in apo form. His-tagged S100P was purified by a nickel sepharose column and 
the N-terminal tag was cleaved by TEV enzyme. The non-fused protein was purified by 
passing the mixture over a nickel column. 
 DNA coding for human soluble RAGE V domain (aminoacids 23-132), VC1 domains 
(amino acids 23-243) and C1C2 domains (aminoacids 122-347) was amplified via PCR with 
oligonucleotides containing 5′ NdeI and 3′ XhoI restriction sites. The amplified DNA 
sequences were cloned into the NdeI and XhoI sites of pET15b vector to express the 
proteins with an N-terminal hexa-histidine tag followed by a thrombin cleavage site.  
Recombinant plasmids with V, VC1, C1C2 RAGE domains were transformed in E. coli 
Origami(B) DE3 (Novagen). Cells were grown at 37°C till an O.D.of 0.7. Protein expression 
was induced with 0.5mM IPTG and growth was allowed for 6 hours at 20°C.  Cells    were  
harvested and lysed in 20mM phosphate, 500mM NaCl, 1mM PMSF, pH 7.4. The lysate 
was first purified on HiTrap chelating HP column (GE Healthcare) and eluted with 20 mM 
phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4.  Following dialysis in 20 mM 
phosphate pH 6.0, 150 mM NaCl, the His6 tag was removed by thrombin cleavage for an 
overnight period at room temperature. The protein without fusion tag was then purified by 
cation exchange in MonoS (GE Healthcare) with a linear gradient from 150-850 mM NaCl. 
Fractions containing the pure protein were pooled and concentrated. The C1C2 domain was 
expressed in E. coli BL21 (DE3) Gold cells in the insoluble fraction. The protein was 
refolded in the nickel column during purification. For cell line experiments, all proteins 
were prepared in PBS buffer, pH 7.4. For NMR experiments the same were prepared in 20 
mM Hepes, 100 mM NaCl, pH 7.2. For titration of S100 proteins with more than one 
cysteine residues with RAGE, the S100s were first reduced by DTT which was then washed 
out under reducing conditions. 
 
S100 proteins treatments 
Cells were seeded in 96-well plates (1x103 cells/well). After 24 hours they were treated with 
various concentrations of recombinant S100 proteins (0.1 – 1 – 10 – 100 – 1000 nM) for 72 
hours. For each S100 protein, the concentration with maximum effect on cell proliferation 
was determined, assayed by the MTS assay (Promega, Madison, WI, USA). In brief, 1000 
cells in 100 µl medium were seeded in each well of 96-well plates. At the end of the 72-h 
incubation period with the recombinant S100 proteins, the cells were incubated with 20 µl of 
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a MTS/PMS mixture (MTS/PMS ratio: 20:1) in each well of 96-well plates for 2 h at 37 °C 
in a humidified incubator with 5% CO2 to allow viable cells to convert the tetrazolium salt 
into formazan. The conversion to formazan was determined by measuring the absorbance at 
490 nm using a PerkinElmer Victor plate reader (PerkinElmer, Shelton, CT, USA). 
The cells were treated with S100 proteins at the optimal concentration and their growth 
curve was evaluated between 24 and 120 h of treatment, by the MTS assay (Promega, 
Madison, WI, USA). 
 
RAGE domains treatments 
Cells were treated with S100 proteins along with different concentrations of recombinant 
RAGE extracellular domains (V, VC1, C1C2; 0.01-0.1-1-10-100 nM) and the optimal 
concentration of RAGE domains was established by the MTS assay.  The RAGE domain 
which binds to each S100 protein and inhibits it from stimulating cell proliferation was 
determined. 
 
NMR experiments 
 
The experiments for protein assignment and mobility measurements of holo S100P and V-
domain of RAGE where performed on protein samples at concentrations ranging between 
0.4 and 1 mM on Hepes buffer at pH 7.2. NMR experiments were acquired on Bruker 
AVANCE 900, AVANCE 800, AVANCE 700 and DRX 500 spectrometers, equipped with 
triple resonance cryo-probes at 298 K and 310 K. All spectra were processed with the 
Bruker TOPSPIN software packages and analyzed by the program CARA (Computer Aided 
Resonance Assignment, ETH Zürich). The backbone resonance assignment of 15N, 13C 
enriched holo-S100P domain was obtained by the analysis of HNCA, HNCACB and 
CBCA(CO)NH spectra performed at 310 K on a 500 MHz spectrometer. The assignment of 
1H-15N HSQC and 1H-15N TROSY S100P spectra at 298 K were derived from data at 310 K, 
integrated by the analysis of HNCA spectra at 298 K. The interaction of S100 proteins with 
V-domain, VC1- and C1C2-tandem domains was monitored by 1H-15N HSQC and 1H-15N 
TROSY spectra. 
  
Results 
The SW480 and PANC-1 cell lines express RAGE on their membrane and previous studies 
have shown that the activation of this receptor by S100P stimulates cell proliferation in these 
cell lines. In our study we performed a cell-based assay comparing the effects of different 
 77 
S100 proteins on the proliferation of these two well characterized tumour cell lines. Cells 
were seeded in a 96 well plate at a density of 1000 cells/well in 100 µl of medium with 10%  
 
FBS. After 24 hours, the medium was removed and cells were treated with S100 proteins 
diluted in the serum-free medium. 
The effect of recombinant S100A1, A2, A4, A5, A12, A16 and P on cell proliferation was 
assayed after 72 hours of treatment. For each cell line, a dose-response curve was plotted, 
treating the cells with the S100 proteins at concentrations ranging between 1 nM and 1 µM.  
In both the cell lines, the S100 proteins triggered a dose-dependent effect on cell 
proliferation, except for S100A16, which stimulates the proliferation of SW480 but not of 
PANC-1 cell line. As shown in fig. 1, our data confirm the already published results for 
S100P, which exhibits maximum effect on cell proliferation at a concentration of 100 nM. 
Moreover, we found that some S100 proteins exert maximal effect at the same concentration 
(S100A1, A2, A12, A16), while others (S100A4, S100A5) are more effective at lower 
concentrations (10 nM).   
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Figure 1A: Dose response curve of Panc-1 cells treated with different concentrations (0, 1, 
10, 100, 1000 nM) of S100 proteins. 
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Figure 1B:  Dose response curve of SW480 cells treated with different concentrations (0, 1, 
10, 100, 1000 nM) of S100 proteins. 
 
From our data we can also elicit that S100A12 at micromolar concentration has an inhibitory 
effect on cell proliferation, as already reported for S100B, while the other S100 proteins 
have a positive effect on cell proliferation at any tested concentration. 
The effect of S100 proteins on cell proliferation was also evaluated by measuring the growth 
curve of SW480 and PANC-1 treated for 24-96 hours with a single concentration of S100 
proteins. 
The cells were seeded as reported previously and treated with 100 nM S100P, A1, A2, A12 
and A16; with 10 nM S100A4 and A5 and with 1 µM S100A12. Results shown in fig. 2 
confirm the stimulatory effect of nanomolar concentrations of S100 proteins in both SW480 
and PANC-1 cell proliferation, as observed for the dose-response curves measured at 72 
hours. S100A12 has different effects on cells proliferation at different concentrations. The 
cells treated with 100 nM S100A12 grow faster than untreated cells while cells treated with 
1 µM S100A12 have a lower growth rate respect to untreated cells. 
For S100A16 a stimulatory effect is observed on SW480 cell proliferation but not on 
PANC-1.  
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Figure 2A: Growth curves of Panc-1 cells treated with different S100 proteins upto 96 
hours. 
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Figure 2B: Growth curves of SW480 cells treated with different S100 proteins upto 96 
hours. 
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Next, the role of the different domains of RAGE in ligand binding was investigated through 
competition experiments on the same cell lines and NMR studies in vitro. Cells were treated  
with both S100 proteins and soluble RAGE domains (V, VC1, C1C2) and the competition 
between soluble and membrane RAGE was expected to modulate the effect of S100 proteins 
on cell proliferation. S100A1, A2, A5, P are reported to interact with RAGE V-domain, as 
assayed by SPR experiments. Our competition experiments (fig. 3) confirmed these 
interactions, since the presence of V or VC1 domains but not C1C2 inhibit cell proliferation 
triggered by S100A1, A2, A5 and S100P. On cells treated with 100 nM S100A12 only VC1 
and C1C2 but not V domain inhibits the stimulatory effect on cell proliferation, providing 
new evidences on the pivotal role of C1 domain in the binding of this S100 protein.  
 
 
 
V and VC1 domains of RAGE inhibit S100A1-stimulated cell proliferation but not C1C2. 
 So S100A1 interacts with the V-domain of RAGE. 
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V and VC1 domains of RAGE inhibit S100A2-stimulated cell proliferation but not C1C2. 
 So S100A2 interacts with the V-domain of RAGE. 
 
 
V and VC1 domains of RAGE inhibit S100A4-stimulated cell proliferation but not C1C2. 
With V-domain the inhibitory effect is less. So S100A2 interacts with the V-domain of 
RAGE with low affinity and with VC1 tandem domain with a higher affinity. 
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V and VC1 domains of RAGE inhibit S100A5-stimulated cell proliferation but not C1C2. 
 So S100A5 interacts with the V-domain of RAGE. 
 
 
C1C2 domain of RAGE inhibits S100A12-stimulated cell proliferation but not V or VC1 
domains. So S100A12 interacts with the C1C2-domain of RAGE. 
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V and VC1 domains of RAGE inhibit S100P-stimulated cell proliferation but not C1C2.  
So S100P interacts with the V-domain of RAGE. 
 
 Figure 3: Growth curves of Panc-1 cells from competition experiments: effect of soluble 
RAGE domains on cells treated with S100 proteins. 
 
Interesting are also the results collected on S100A4. The interaction of this protein with 
RAGE was investigated here for the first time. Our data show that the addition of VC1 
inhibits the effect of S100A4 on cells while V-domain is effective only at higher 
concentration and C1C2 doesn’t have any effect. All together these data suggest that 
S100A4 interact with VC1 tandem domain and with V domain with lower affinity but not 
with C1C2 tandem domain. 
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      Table 2: Effect of S100 proteins on cell proliferation and RAGE activation 
S100 
protein 
Increased 
PANC-1 
proliferation 
Increased 
SW480 
proliferation 
Competitive 
RAGE domain 
     NMR  
 interaction 
S100A1 yes yes V - VC1   
S100A2 yes yes (V)b- VC1 V 
S100A4 yes yes V - VC1 V 
S100A5 yes yes V - VC1 V-VC1 
S100A12 yes/noa yes/noa (VC1)b - C1C2 C1C2 
S100A14 no no     
S100A16 no yes   V 
S100P yes yes V - VC1 - C1C2 V-VC1 
 
 
The real binding capability of the investigated S100 proteins toward RAGE domains was 
then assessed in vitro by NMR. 
Alteration of chemical shift, signal disappearance and line broadening in 1H-15N HSQC 
spectra are considered as evidences of interactions between S100 proteins and RAGE. 15N 
labelled samples of Ca2+- S100A2, -S100A5, -S100A12 and -S100P were titrated with 
unlabeled V-domain of RAGE. All the investigated proteins but S100A12 exhibit a general 
broadening of resonances with disappearance of several peaks and several shifts when V-
domain was added to a molar ratio of 1:2 (V-RAGE:S100). Similar effects were observed 
when C1-C2 tandem domain of Rage was added to Holo-S100A12. 
 
 
 
   Ca2+-S100A2  Ca2+-S100A2 + V-RAGE                              Ca2+-S100A5  Ca2+-S100A5 + V-RAGE   
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                   Ca2+-S100A12  Ca2+-S100A12 + C1C2-RAGE                   Ca2+-S100P  Ca2+-S100P + V-RAGE 
 
 Figure 4: Overlay of 1H 15N HSQC spectra of Ca2+-S100 proteins titrated with RAGE 
domains in 2:1 ratio. Buffer conditions: 20 mM Hepes, 100 mM NaCl, pH 7.2. Temp:298 K. 
Spectra taken at 800 MHz. 
 
The interaction of holo-S100P with extracellular domains of Rage was investigated in more 
detail.  
Structural data representative of interactions between S100P and V-domain of RAGE in 
solution were obtained by monitoring the reciprocal effects on 1H-15N HSQC and Trosy 
NMR spectra. The backbone assignment of apo S100P was already available on BMRB 
database while the holo form was assigned in the present work. Backbone resonances of V-
domain of RAGE were also reassigned. The spectral quality for holo S100P is largely better 
at 310 K than at 298 K. Thus all the experiments for backbone assignment were performed 
at the physiological value of 310 K. Holo S100P exists as homodimer in solution and during 
size exclusion is eluted as a single peak.  
Measurements of longitudinal (R1) and transverse (R2) relaxation rates of backbone amide 
nitrogens at 700 MHz 1H Larmor frequency and 310 K have been performed on a 15N-
enriched sample of holo S100P. Estimates of R1 and R2 values under the chosen 
experimental conditions of magnetic field and temperature were obtained using the program 
HydroNMR (48) and the X-ray structure taken from PDB (30).  
The experimental and theoretical R1 and R2 values are reported in Figure 5.  The observed R1 
and R2 data are in excellent agreement with the theoretical expectations for a dimeric form 
of S100P without any indication of self aggregation at this concentration.  
 
 88 
 
    
 
Figure 5:  NMR relaxation data for Holo-S100P and for its adduct with V-RAGE (data collected at 310 
K). The calculated (grey bars) and experimental (filled circles) backbone 15NH R1 and R2 values for the 
isolated Holo-S100P are shown in A and B, and those of its complex with V-RAGE in C. The agreement 
between experimental and calculated R1 and R2 values for the Holo-S100P is excellent and only few residues 
at the C-terminal and some residues on the loop between the two EF-hand motif experience fast internal 
mobility revealed by the large R 1 and the small R 2 values. Also the experimental R1 data for the Holo-
S100P/V-RAGE adduct agrees with the theoretical expectations while R2 are not reported because the large 
errors due to the low signal-to-noise ratios in the spectra. 
 
 
The titration of 15N labeled holo-S100P with unlabeled V-domain until a molar ratio of 2:1, 
resulted in a progressive line broadening of peaks, with shifts and disappearance of signals. 
No further changes in the NMR spectrum of holo-S100P were detected at higher 
concentrations of V-domain. To improve the quality of the spectra the titration was repeated 
on a 2H-13C-15N sample of holo-S100P. 
Comparable effects on holo-S100P spectra were obtained by performing the titration with 
VC1-tandem domain. To complete the analysis of the protein-protein interface, a 15N labeled 
sample of V-domain was titrated with holo-S100P until a molar ratio of 1:2. The analysis of 
the corresponding 15N HSQC spectra revealed a set of signals experiencing chemical shift 
variation. Chemical shift changes on holo-S100P and V-domain are reported in figure 6. 
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From the analysis of the 1H and 15N chemical shift variations between isolated holo-S100P 
and the complex it is clearly evident that the protein regions formed by Helix-4, Helix-3 and 
the loop interconnecting Helix-3 with Helix-2 are strongly affected by the interaction.  
                             
                  
Figure 6: Plot of the 1H-15N HSQC chemical shifts ({[(δH)2 + (δN/5)2]/2}1/2) per residue 
observed in 0.4 mM Holo-S100P in presence of V-RAGE (0.2 mM) (A), and in 0.2 mM of 
V-RAGE in presence of Holo-S100P (0.4 mM) (B). 
 
The chemical shift mapping and the related interaction surfaces have been exploited to 
determine a possible structural model for the interaction of the holo-S100P with V-domain 
of RAGE using the program HADDOCK (Dominguez et al., 2003). To model the structure 
of the complex between holo-S100P and the V-domain of RAGE, we performed docking 
calculations using as input a computer homology model of holo-S100P based on the X-ray 
structure 1J55 and the X-ray structure of the VC1 tandem domains. NMR data were used to 
derive the interaction restraints on the two proteins. From the analysis of the energetic and 
scoring functions, it appeared that, essentially, only one cluster experienced a far better 
scoring function with respect to the others with larger interaction surfaces and a much lower 
average number of ambiguous restraints. This indicates better agreement with the 
experimental data. The lowest-energy complex for this cluster is shown in Fig. 7. 
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Figure 7: Structural models of Holo-S100P-VC1 complex generated by molecular docking. 
Lowest HADDOCK score structure of cluster 1 is represented. Holo-S100P is shown in 
orange, while VC1 domains are shown in cyan (V) and pink (C1).  
 
Discussion 
Some members of S100 family such as S100B, S100P and S100A12 are secreted or released 
in the extracellular space where they activate the RAGE signaling pathway by interacting 
with the extracellular domains of the receptor. The interaction with RAGE is supposed to be 
the general mechanism for the autocrine and paracrine activity of S100 proteins. However, 
the experimental data on activation of RAGE by these calcium binding proteins available so 
far are too scattered and still largely incomplete. Our results on a broad set of S100 show 
that all the investigated proteins trigger the RAGE signaling increasing cell proliferation 
with different potency. S100A4 and S100A5 exhibit the maximum activity already at 
concentration of 10 nM while all the others require ten times larger concentration. The NMR 
data in vitro and the competition experiments carried out on the same cell lines support a 
model whereby all the S100 proteins induce an increase of cell proliferation by a direct 
protein-protein interaction with the extracellular domains of RAGE. The NMR spectra show 
that all the investigated holo-S100s interact with at least one of the extracellular domains of 
RAGE with an affinity in the micromolar range or lower. In particular, all but S100A12 
exhibit relevant alteration of the 1H-15N HSQC spectra in presence of V or VC1 domains. 
The role of V, VC1 and C1C2 has also been assessed by performing competition 
experiments on cell culture where they abolish the proliferative effects of the S100 proteins 
to which they bind. From our results it is clear that V-domain plays the leading role in 
binding to most S100 proteins and in activation of the receptor. This can be explained by the 
homology of V domain with the region of immunoglobulin responsible for binding to 
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epitope of antigens and its structural features similar to cell adhesion molecules. Activation 
of RAGE involves oligomerisation of the receptor modulated by the ligand binding.  
According to the most recent hypothesis, pre-assembled RAGE receptors are tethered by 
S100 oligomers and switched in the activated form. In this respect, structural details of the 
binding mode of S100 ligands on the V-domain can provide information on the self-
assembled S100 species involved in RAGE oligomerisation and on the mechanisms that 
tune extracellular activity of these calcium binding proteins. 
The model here proposed for adduct between S100P and V-domain of Rage shows that the 
negatively charged surface of the calcium-binding protein  in between helix 3 and 4, interact 
with the region of V-domain formed by strands 2, 5, 6 and by some interconnecting loops. 
A similar binding mode has recently been proposed for S100B that interacts with the same 
negatively charged region on a positively charged area of V-domain not far from that here 
reported for S100P. Although without any functional relevance, it is interesting to note that 
in the available octameric S100B crystal structure the interacting surfaces responsible for 
binding to V-domain are solvent-exposed and accessible for the interaction. For S100A12 
that binds to RAGE at the C1 domain, the available hexameric crystal structure shows a 
completely different arrangement of the dimmers. The interacting surface of S100P and 
S100B are inward-facing and not fully accessible for the interaction.  
In conclusion, our data show that all the investigated S100 proteins increase cell 
proliferation in the investigated cancer cell lines. They trigger the activation of RAGE by 
binding to at least one of the three extracellular domain of Rage. In most cases, the 
interaction involves the V-domain, although S100A12 shows a different preference. The 
region between helix 3 and 4 of S100 proteins and the surface formed by strands 2, 5, 6 and 
some interconnecting loops seem to play a leading role in ligand recognition and in the 
subsequent receptor activation. 
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    3.4 Paramagnetic Probe attachment to S100 proteins for interaction studies 
 
Two mutations, Q65G and K72E in EF-2 of S100A5 (based on sequence alignment with 
calbindin) could successfully convert the calcium binding site to a lanthanide binding site. 
The Ca2+ at EF-2 of this mutant protein could be selectively substituted with lanthanides. 
 
                       
               
 Red: 15N HSQC of Ca2+ S100A5  Blue: 15N HSQC of 1 Ca2+ 1Yb3+ S100A5 
                                            Temp: 298 K           Spectra taken at 700 MHz 
     Figure 1: Overlay of Ca2+ S100A5 with 1 Ca2+ 1 Yb3+ S100A5 mutant 
 
  
This lanthanide derivative of S100A5 was used to study the interaction with the V-domain 
 of RAGE. 
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                                   A                                                                                 B 
 
                         15N V-RAGE                                                                       15N V-RAGE   
15N V-RAGE + unl S100A5 mut (1Ca2+ 1Lu3+)          15N V-RAGE + unl S100A5 mut (1Ca2+ 1Yb3+)  
                               Temp: 298K    Spectra taken at 700 MHz      S100:RAGE   2:1 
Figure 2: Overlay of HSQC of V-RAGE with the same titrated with A) Ca2+ S100A5 
mutant and B) 1 Ca2+ 1 Yb3+ S100A5 mutant. 
 
Titration of RAGE with Yb3+ S100A5 caused the disappearance of several peaks from the  
spectrum. Moreover, no significant shifts or appearance of new peaks of the complex due to 
the paramagnetic effect could be detected. As such this lanthanide derivative could not be 
used further for structural characterisation of the complex. 
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Introduction 
Conformational flexibility is often a crucial feature for proteins to perform their 
function in solution.1;2 During biological processes, different kinds of conformational 
changes may occur such as side chain rotations, loop motions, interdomain reorientations, 
intermolecular rearrangements, random-coil motions in unfolded proteins or protein regions. 
NMR spectroscopy has long been used for structural and dynamic studies of proteins in 
solution. In NMR experiments, solution conditions such as temperature, pH and salt 
concentration can be adjusted to closely mimic the physiological fluid where the protein 
performs its function. Most protein dynamic studies are focused on the analysis of relaxation 
data (R1, R2 and NOE) and provide information on the protein tumbling times and on the 
presence of local motions.3;4 Paramagnetism-based restraints have been shown to monitor 
the presence of conformational rearrangements among protein domains,5 to detect the 
presence of minor interconverting conformations,6-8 to determine whether regions in the 
conformational space must be occupied or cannot be occupied by protein complexes,9;10 and 
to provide information on the maximum occurrence (MO) of any conformation that is 
sterically allowed.11  
The MO strategy is focused on determining the maximum weight that any given 
conformation can have in any conformational ensemble in agreement with all available 
experimental data obtained, e.g., through solution NMR or small angle X-ray scattering 
(SAXS) measurements.11-13 These measurements in fact provide weighted averages over all 
the conformations experienced by the system. They cannot be used to recover the actual 
protein conformational ensemble, but do provide the maximum percent of time that a system 
can spend in any conformation.  
Calmodulin (CaM) is a calcium(II) EF-hand protein, which contains two similar 
globular domains connected by a flexible linker.14 This structural feature makes it easy for 
the two domains to adopt a variety of different orientations with respect to one another. In 
order to describe the interdomain conformational variability, lanthanide ions were used as 
paramagnetic probes, and NMR experiments were performed to obtain pseudocontact shifts 
(pcs) and residual dipolar couplings (rdc).5;12 These data were used as restraints to calculate 
the conformations with largest MO and to analyze the different MO of the possible protein 
conformations. The N60D CaM mutant was actually used to selectively substitute the Ca2+ 
ion located in the second binding site of the N-terminal domain with a paramagnetic 
lanthanide ion (Tb3+, Tm3+ or Dy3+).15 The same analysis was performed to detect the 
conformational heterogeneity of CaM bound to α-synuclein12 or to a peptide from the 
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myelin basic protein (MBP, unpublished results from the CERM laboratory). Pcs and rdc 
restraints were also used to detect slight conformational changes in CaM when bound to 
peptides representing the interaction sequence of two protein partners, the death-associated 
protein kinase (DAPk) and the DAPk-related protein 1 (DRP-1), on passing from crystal to 
solution.16 The results suggest that the two domains are relatively flexible with respect to 
one another in free CaM and that mobility changes after target peptide binding.17 
The advantage provided by the paramagnetism-based restraints is based on the 
possibility to retrieve the magnetic susceptibility anisotropy tensors of the different metals 
from the pcs values collected for nuclei belonging to the same domain where the metal ion is 
coordinated (the N-terminal domain in this case). The pcs and rdc values collected for the 
nuclei belonging to the other domain act as reporters of the interdomain conformational 
variability. In fact, they are the weighted average of the pcs and rdc values corresponding to 
all sampled conformations, and such values are determined by the same magnetic 
susceptibility anisotropy tensors calculated for the metal bearing domain which also act as 
orientation tensors. 
The MO value calculated for each conformation decreases towards the actual 
probability when the number of independent experimental restraints is increased. MO values 
of less probable conformations are expected to decrease more than those of the most 
probable conformations. The resulting larger spreading of the MO values calculated for the 
different conformations likely permits to better identify those with largest probability. 
In this work we analyze how MO values are affected by the availability of restraints 
provided by paramagnetic metal ions located in both domains of CaM. Pcs and rdc collected 
for the N-terminal domain, when the paramagnetic metal is placed in the C-terminal domain 
of CaM, actually represent independent information and provide a different perspective on 
the protein conformational variability. Therefore, when the paramagnetic restraints obtained 
from both the metal positions are used together, the difference in the MO values of highly 
occurring and lowly occurring conformations is expected to increase. Furthermore, besides 
providing additional information on the relative position of the domains, the addition of 
these restraints could also remove some of the possible “ghost” solutions determined by the 
mathematical form of the pcs and rdc equations.12;13  
In order to place a metal ion in the C-terminal domain of CaM, the Caged Lanthanide 
NMR Probe 5 (CLaNP-5)18 was attached to the H107C/N111C CaM mutant. This tag was 
chosen because it can bind rigidly to the protein backbone through two cysteine residues.19 
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Rigid binding is essential to obtain the correct magnetic susceptibility anisotropy tensor 
from the pcs of the attached domain and to easily interpret the pcs of the other domain.20  
  
 Materials and Methods  
Protein preparation 
15N labeled N60D CaM was purchased from ProtEra s.r.l. (Florence, Italy, 
www.proterasrl.com). The NMR samples were prepared in 20 mM MES, 200 mM KCl, pH 
6.8. For the attachment of the ClaNP-5 tag, the H107C/N111C mutations were introduced in 
wild type CaM via site-directed mutagenesis. 15N labeled his-tagged H107C/N111C CaM 
was expressed in E. coli BL21(DE3) Gold cells and purified with Ni-NTA column and size 
exclusion chromatography in the same buffer as the N60D mutant. The entire process of tag 
attachment was performed under reducing conditions. The Ca2+-CaM mutant was incubated 
with 5 mM DTT for 30 mins to reduce all possible disulfide bridges and ensure that the 
protein existed in monomeric state. DTT was then washed out under reducing conditions. 
The protein was diluted to a concentration of 30 µM. Seven equivalents of Ln3+-loaded 
CLaNP-5 (Ln3+ = Lu3+, Yb3+ and Tm3+) was added to it. The mixture was incubated 
overnight at 4 °C for the reaction to reach completion. To separate the tagged monomeric 
protein from aggregates and free tag present in solution, a purification was performed using 
a Superdex 200 gel filtration column. Approximately three-fourth of the total protein was 
found to be monomeric and reacted while the remaining one-fourth formed aggregates. In all 
the above steps of tagging, the CaM mutant was prepared in 20 mM MES, 200 mM KCl, 20 
mM CaCl2, pH 6.8. An excess of calcium was always used in the buffer to avoid exchange 
of Ca2+ from the binding sites with any free Ln3+ ions present in the tag solution.  
 
NMR Measurements 
All NMR experiments were performed at 298 K. 15N labeled N60DCaM (0.4 mM) 
was titrated to (Ca2)N(Ca2)C-CaM and (CaLn)N(Ca2)C-CaM (Ln3+ = Tm3+, Tb3+ and Dy3+) by 
addition of small amounts of calcium(II) and subsequently lanthanide(III) solutions. The 
titrations were performed by following the 1H-15N HSQC spectra at 700 MHz as previously 
reported.15 1H-15N IPAP HSQC spectra were also acquired to obtain the rdc values. 
1H-15N HSQC and IPAP-HSQC spectra of Ln3+-CLaNP-5 Ca4CaM (Ln3+ = Lu3+, Yb3+ and 
Tm3+) were acquired at 298 K and 700 MHz. HNCO,21 HNCA,22 CBCACONH21 and 
HNCACB23 experiments at 500 MHz were performed on 15N and 13C labeled 
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H107C/N111C CaM tagged with Ln3+-CLaNP-5 (Ln3+ =Lu3+ and Yb3+) to obtain the 
backbone assignment. The backbone resonance signals of Tm3+-CLaNP-5 Ca4CaM were 
assigned based on the assigned 1H-15N HSQC spectra of the diamagnetic Lu3+ form and of 
the paramagnetic Yb3+ form.  
Pcs data were obtained from the difference in 1H chemical shift between 
corresponding nuclei in the paramagnetic and diamagnetic CaM derivatives. Rdc data were 
obtained as the difference in the doublet splitting in the indirect 15N dimension in 1H-15N 
IPAP-HSQC spectra (15) between the paramagnetic form and the diamagnetic form. 
 
Maximum occurrence (MO) calculation of CaM conformations 
The pcs values measured for the domain where the paramagnetic metal is located 
were used to calculate the magnetic susceptibility anisotropy tensors of the different metals. 
For the N60D (CaLn)N(Ca2)C-CaM samples, the program FANTASIAN24 was used to 
determine the anisotropy tensors. For the Ln3+-CLaNP-5 Ca4CaM samples the programs 
FANTASIAN and PARAMAGNETICCYANA-2.125;26 were used to determine the 
anisotropy tensors and the position of the metal ions with respect to the backbone of the C-
terminal domain. These tensors were then fixed in all subsequent calculations.  
The program for the calculation of the MO of any given conformation11 was 
modified to incorporate paramagnetic restraints arising from metal ions located in both 
protein domains. In this way, pcs and rdc measured for the C-terminal domain when the 
paramagnetic metal is located in the N-terminal domain could be analyzed together with pcs 
and rdc measured for the N-terminal domain when the metal is located in the tagged C-
terminal domain. More details are reported in the Supporting Information S1 . 
A total of 400 conformations with different inter-domain orientations were obtained 
through the program RANCH.11;27 The MO values of each conformation were calculated 
from the paramagnetic restraints (pcs and rdc) obtained for the different lanthanides located 
in either the N- or the C-terminal domain. Taking each conformation as a starting point, a 
simulated annealing minimization was performed to generate an ensemble with a maximum 
of 15 other conformations which, together with the starting conformation, provides the best 
fit of the experimental data. Such fit was performed by minimizing a target function (TF) 
defined as the sum of the squared difference between the values obtained from the weighted 
average of pcs and rdc calculated for all conformations of the ensemble and the 
corresponding experimental data (see Eq. S2). The weight of the starting conformation was 
fixed in the minimization, and several calculations were repeated by changing the weight of 
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such conformation. The MO value of each conformation was calculated as the weight for 
which the TF is 10% larger than the minimum value. More details are reported in the 
Supporting Information S1. 
  
 Results and discussion 
 
Synthetic Tests 
Synthetic tests were performed by simulating the conformational heterogeneity of a 
two-domain protein like calmodulin. This was done by generating a large number (50000) of 
protein conformations using a Gaussian probability distribution around one selected 
conformation. Pcs and rdc data were simulated from the average of the rdc and pcs values 
obtained for the different conformations. Pcs and rdc data were calculated for four or five 
ions with different anisotropy tensors all located in one domain or distributed between the 
two domains.  
These simulated data where then used to obtain the MO of the conformation at the 
center of the Gaussian distribution and of conformations with the orientation of the C-
terminal domain described by Euler angles whose values were varied by ±50° (standard 
deviation of the distribution) from the central conformation. The calculations indicated that 
the conformation at the center of the Gaussian distribution can be better identified through 
the MO values when the metals are distributed in two domains rather than being all in a 
single domain. In fact, the difference in the MO between the central conformation and the 
conformations at one standard deviation increases when pcs and rdc data are referred to 
metals distributed in the two domains, rather than being all located in the same domain. 
More details are shown in the Supporting Information S2. This finding is not obvious as it 
has been proven that the amount of information for the characterization of the interdomain 
mobility is larger when rdc arising from metals with different anisotropy tensors without any 
main direction in common are all located in the same domain, with respect to the case of 
having them distributed in the two domains, in the absence of experimental errors and 
without using pcs.28 
 
 
 
 105 
 
N60D (CaLn)N(Ca2)C-CaM 
Pcs and rdc for (CaLn)N(Ca2)C-CaM (Ln3+ = Tm3+, Tb3+ and Dy3+) were measured in 
buffer 20 mM MES, 200 mM KCl and pH 6.8, the same used for the CLaNP-5 Tagged CaM 
samples. Some differences can be appreciated from those previously measured in 400 mM 
KCl, pH 6.5.12 
The structure of the CaM domains in solution was fixed to the coordinates deposited 
in PDB 1J7O and 1J7P.29 These structures were chosen because refined with an extensive 
use of rdc derived by external orienting media. The position of the lanthanide ions in the 
N60D (CaLn)N(Ca2)C-CaM samples was fixed to the coordinates of the calcium ion in the 
second binding loop of the N-terminal domain.  
The best fit of the pcs of the N-terminal domain amide protons to the protein 
structure provided the magnetic susceptibility anisotropy tensors reported in Table 1. They 
are in good agreement with those previously obtained.5;12 The quality of the fit is good as 
shown in Figure 1A.  
The best fit of the rdc of the C-terminal domain amide protons to the protein 
structure provided the anisotropy tensors reported in Table 1. As previously found, they are 
sizably smaller that those obtained from the pcs of the N-terminal domain nuclei. The good 
quality of the fits, shown in Figure 1B, however indicate that the data are in good agreement 
with the protein structure, which thus moves as a rigid body, so that the obtained tensors are 
averages of the magnetic susceptibility anisotropy tensors positioned in the N-terminal 
domain as seen from a nucleus in the C-terminal domain.  
 
CLaNP-5 Tagged CaM 
Paramagnetic ions were placed in the C-terminal domain of CaM using the CLaNP-5 
tag.18 The mutation H107C/N111C was performed in order to allow the tag to be attached to 
the protein through disulphide bonds. The residues to be mutated were chosen i) positioned 
on one helix (the second of the C-terminal domain) in order to provide rigidity to the 
CLaNP-5 tag; ii) so that the cysteine side chains are exposed on the surface of the structure 
with the C atoms pointing away and the C atoms not closer than 6 Å and nor farther than 
10 Å from one another; iii) in order to attach the tag in a position far enough from the N-
terminal domain to avoid steric clashes that may affect the conformational heterogeneity of 
the protein. 
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Lu3+-CLaNP-5 was used as the diamagnetic reference. The 1H-15N HSQC spectrum 
of Lu3+-CLaNP-5 H107C/N111C CaM is similar to that of Ca4CaM with differences limited 
to the residues in close proximity to ClaNP-5, indicating that the protein structure is 
maintained after binding of the tag (see Figure S4). Both Yb3+ and Tm3+ CLaNP-5 induced 
positive paramagnetic shifts, which in the Tm3+ form are much larger than in the Yb3+ form 
(see Figure 2), due to the larger magnetic susceptibility anisotropy of Tm3+. 
The program PARAMAGNETICCYANA-2.1 was first used to determine the 
position of the metal ions with respect to the C-terminal domain structure (PDB 1J7O29) 
using typical values for the magnetic susceptibility anisotropies and the observed pcs 
measured in the presence of Tm3+ or Yb3+ bound to the tag. The magnetic susceptibility 
anisotropy values were then refined using the program FANTASIAN through the best fit of 
the pcs to the C-terminal domain structure and the relative calculated position of the 
lanthanides. The two programs were cycled iteratively until convergence of both the metal 
position and the susceptibility anisotropy tensors was reached.  
The observed pcs values fit very well versus the calculated data (Figure 3A). The 
resulting axial and rhombic components of the magnetic susceptibility anisotropy tensors as 
well as the Euler angles providing the orientation of the tensors are reported in Table 1. 
These results are in agreement with the values reported in Keizers et al.18 The z-axes of the 
Yb3+ and Tm3+ tensors are parallel, and the x- and y-axes of the two metals experience 
difference in the orientation of only 21° (Fig. 4). The calculations show that the metals are 
located at about the same distance from the protein backbone as in Keizers et al.18 The 
positions of Yb3+ and Tm3+ are in fact similar for the two metals and at distances of 8.3 Å 
and 6.5 Å from the Cα atoms of residues Cys-107 and Cys-111, respectively. The magnitude 
of the calculated anisotropies and the correct definition of the lanthanide position indicates 
that the CLaNP-5 probe binds Ca4CaM rigidly. 
The rigidity of the tag is confirmed by the rdc values measured for the C-terminal 
domain amide protons. These rdc, when fitted to the domain structure, provide a nice 
agreement with the values calculated from the best fit tensors. This is clear in particular for 
the Yb3+ sample, the C-terminal domain nuclei of which are less affected by paramagnetic 
line broadening due to the smaller susceptibility tensor of Yb3+ than that of Tm3+, which 
causes a smaller Curie relaxation (Figure 3B). The best fit anisotropy tensors (ax= 8.110-
32 m3, rh= 2.510-32 m3) are actually very similar to those calculated from the pcs, 
indicating that no (or very modest) reduction due to motional averaging occurs. When the 
measured rdc are compared with the rdc values calculated from the tensor derived from pcs, 
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a good agreement is indeed observed (Figure 3B), the differences between calculated and 
observed data being all within 2 Hz. 
Due to the much smaller magnetic susceptibility anisotropy of Yb3+ with respect to 
Tm3+, a reliable set of pcs and rdc for the N-terminal nuclei could be observed only for the 
Tm3+ derivative. The rdc, quite reduced with respect to those measured for the C-terminal 
domain, can be described by a single average tensor. The latter was obtained by fitting the 
rdc to the N-terminal domain CaM structure. As expected, the calculated average tensor is 
sizably smaller than that obtained from the C-terminal domain pcs data (Table 1) as a 
consequence of extensive orientation averaging. The fit of the observed rdc versus the 
calculated values is shown in Fig. 3C. Pcs of the N-terminal domain NH nuclei were also 
collected, and they are reported in Fig 3D. 
 
MO analysis 
Calculations of the MO values for 400 CaM conformations randomly generated have 
been performed using the derived magnetic susceptibility anisotropy tensors and the pcs and 
rdc data observed for the domain without the paramagnetic metal. MO values are obtained 
from the largest weight that each of the 400 conformations can have when included in any 
possible ensemble with other 15 conformations with different weights. This ensemble was 
found as the family of structures in best agreement with the experimental data by 
minimizing the target function (TF), defined as a measure of the disagreement from the 
experimental data of the pcs and rdc values calculated according to the ensemble itself (see 
Materials and Methods and Supporting Information S1 for further details). It was checked 
that increasing the number of conformations above 15 does not decrease the TF, so that such 
number of conformations was chosen for the calculations. During the minimization, the 
weight of the fixed conformation (one of the 400 randomly generated conformations) was 
changed. The MO of such conformation was set to the largest weight for which the TF is 
smaller than a given threshold. The latter was defined 10% larger than the lowest possible 
TF value. 
The results obtained for the Tb3+, Tm3+ and Dy3+ ions positioned in the N-terminal 
domain provide the map of MO values shown in Fig 5A. The position of the C-terminal 
domain of CaM is indicated by an orientation tensor centered in the center of mass of the C-
terminal domain, color-coded with respect to the MO of the corresponding conformation 
from blue (lower than 5%) to red (greater than 30%). Different orientations of the tensor 
reflect different orientations of the CaM C-terminal domain with respect to the N-terminal 
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domain. The minimum for the TF was calculated by generating structural ensembles without 
any fixed conformation, and resulted equal to 0.203, so that a threshold of 0.223 was fixed. 
The overall distribution of the MO values is indeed relatively similar to that previously 
calculated for data acquired with a higher salt concentration in solution and with inclusion of 
SAXS restraints (Figure 3A of Bertini et al.11). As already seen, the conformations having 
the C-terminal domain in the lower right quadrant of the frame have in general low MO, 
while the conformations with the highest MO are clustered in the central part of the 
distribution, corresponding to relatively but not fully elongated conformations.  
The set of rdc data acquired for the N-terminal domain when the Tm3+ tag is placed 
in the C-terminal domain of the CaM mutant was then added to the previous data, and MO 
calculations were repeated for the same 400 conformations. In this case, a minimum for the 
TF was calculated equal to 0.224, so that a threshold of 0.246 was fixed. The number of 
conformations with TF smaller than the defined threshold when their weight was 0.1 
increased from 66 to 248 (Figure 6). As expected, this indicates that the new set of data is 
effective in decreasing selectively the MO of conformations much less sampled or even not 
actually sampled by the system. The MO values are shown in Fig 5B. Figure 7 shows the TF 
values for all the conformations as a function of their weight. The substantial differences in 
the weight at which the TF value starts increasing result in markedly different MO. 
Figure 8 shows the conformations with a difference in the MO values upon inclusion 
of the last set of restraints larger than 0.1. The corresponding orientation tensors are color-
coded with respect to the MO difference from blue (difference in MO of 0.10) to red 
(difference in MO of 0.25). The figure shows that the effect is distributed along all the 
conformational space, for all relative positions and orientations of the C-terminal domain.  
The present calculations, as well as the simulations performed with synthetic data, 
show that although rdc arising from up to 5 metals located in different domains are not fully 
independent,28 differently from when they are all located in the same domain, they are quite 
informative for the determination of the MO of the different conformations when coupled 
with pcs and considering that data are effected by experimental errors. The information on 
the interdomain conformational variability that is contained in the rdc arising from different 
metals placed in the same domain is in fact larger than that contained in the rdc arising from 
the same number of metals but distributed between the two domains.28 In the latter case, 
however, relationships are present among the average rdc-derived tensors and the pcs-
derived magnetic susceptibility anisotropy tensors28 that can profitably assess the 
consistency of the data. We have shown in the simulations reported in the Supporting 
 109 
Information that the use of pcs in the calculations may however compensate the smaller 
information content of rdc on the protein conformational distribution, and may make the 
distribution of the metals in both protein domains preferable. Therefore, the use pcs and rdc 
data arising from metals placed in both protein domains i) permits an internal check of the 
quality of the data from the overall agreement of all sets of the experimental rdc with those 
calculated from the best-fit conformational ensembles and ii) provides a better 
discrimination among the different protein conformations depending on the calculated MO 
values. We are now checking whether this can also be shown by comparing the results of the 
3+0 calculations with the 2+1 calculations. 
  
 Conclusions 
We have shown that the simultaneous use of paramagnetism-based restraints arising 
from paramagnetic metal ions located in different domains of proteins experiencing 
interdomain mobility is quite informative for the determination of the maximum occurrence 
of any conformation. The increase in the information content provided by locating 
paramagnetic ions in different domains is larger than obtained by placing the same number 
of metal ions in the same site especially because of the quite different orientations of the 
magnetic susceptibility anisotropy tensors. In the case of CaM we have shown that the 
maximum occurrence of several conformations is quite reduced by the addition of pcs and 
rdc arising from the presence of a single metal ion rigidly attached to the C-terminal domain 
with respect to the values calculated using three metal ions placed in the N-terminal domain 
of the protein. As a result, the conformations likely experienced by the protein can be more 
accurately mapped.  
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Table 1. Magnetic susceptibility anisotropies and average tensors of the different 
lanthanides in the second calcium binding loop of the N-terminal domain of CaM and in the 
ClaNP-5 CaM. The Euler angles are in the ZYZ convention. 
 
 ax (10
-32m3) rh (10
-32m3) Euler angles (P, T, O) 
Metals in the N-terminal domain – from N-terminal domain pcs 
Tb 35.6 -16.5 1.767a -0.883a 0.709a 
Tm 30.7 -8.5 0.476a -0.510a 1.812a 
Dy 35.5 -12.9 1.317a -0.721a 0.312a 
Metals in the C-terminal domain – from C-terminal domain pcs 
Yb 9.7 -2.6 0.885b -1.715b 1.822b 
Tm 56.3 -6.7 0.834b -1.360b 1.882b 
 
 
ax (10
-32m3) rh (10
-32m3) Euler angles (P, T, O) 
Metals in the N-terminal domain – from C-terminal domain rdc 
Tb 3.1 2.9 -2.625b -0.042b 0.041b 
Tm 2.0 1.0 -0.324b 0.568b -0.160b 
Dy 2.7 -1.6 1.703b 0.049b 0.038b 
Metals in the C-terminal domain – from N-terminal domain rdc 
Tm 3.0 2.9 3.106a 0.301a -0.336a 
awith respect to structure 1J7O; bwith respect to structure 1J7P 
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Figure 1. (A) Observed versus calculated values of pcs of N-terminal domain nuclei for the 
terbium(III), thulium(III) and dysprosium(III) ions substituted in the second binding site of CaM 
N-terminal domain. (B) Observed versus calculated values of rdc of C-terminal domain HN for 
the terbium(III), thulium(III) and dysprosium(III) ions substituted in the second binding site of 
CaM N-terminal domain. 
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  Figure 2 Superimposition of a region of the 1H-15N HSQC spectra of Lu3+ (red), Yb3+ (green)   
and Tm3+ (blue) ClaNP-5 CaM. 
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Figure 3 (A) Observed versus calculated pcs of C-terminal domain nuclei for the Yb3+ () 
and Tm3+ () ClaNP-5 Ca4CaM. (B) Observed versus calculated rdc of C-terminal domain 
HN for the Yb3+-ClaNP-5 Ca4CaM. The solid symbols () indicate the values calculated 
from the best fit parameters (ax= 8.110-32 m3, rh= 2.510-32 m3), the open symbols 
() indicate the values calculated using the pcs-derived tensor. (C) Observed versus 
calculated rdc of N-terminal domain HN for the Tm3+ ClaNP-5 Ca4CaM. (D) Observed pcs 
of the C-terminal domain for Tm3+-ClaNP-5 Ca4CaM. 
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Figure 4. The lanthanide ions (in blue) are placed at a distance of 8.3 Å and 6.5Å from the 
Cα atoms of residues Cys-107 and Cys-111. The orientations of the magnetic susceptibility 
anisotropy tensors are shown for the Yb3+ (magenta) and Tm3+ (brown) metals. The z axes of 
the anisotropy tensors of the two metals are essentially coinciding; the angle between the x 
(and y) axes of the anisotropy tensors of the two metals is 21.4°. 
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Figure 5. Arbitrary orientation tensors centered in the center of mass of the C-terminal 
domain, color-coded with respect to the MO of the corresponding conformation from blue 
(lower than 5%) to red (greater than 30%) for 400 structures generated randomly with 
RANCH. Panel A shows the results obtained from pcs and rdc arising with metals in the N-
terminal domain; panel B shows the results obtained when pcs and rdc of Tm3+-ClaNP-5 
Ca4CaM are also included. 
                           A                                                                            B 
 
         
 
 
Figure 6. Number of conformations as a function of the MO values calculated from the pcs 
and rdc arising with metals in the N-terminal domain (3+0 case) and by including pcs and 
rdc of Tm3+-ClaNP-5 Ca4CaM (3+1 case). 
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Figure 7. TF (describing the best agreement between any conformational ensemble and the 
experimental data) as a function of the weight of the conformation for which the MO is 
calculated. Each curve corresponds to a different conformation. The MO is defined by the 
intersection between the TF curve and the threshold chosen 10% larger than the smallest TF. 
Panel A shows the results obtained from pcs and rdc arising with metals in the N-terminal 
domain; panel B shows the results obtained when pcs and rdc of Tm3+-ClaNP-5 Ca4CaM are 
also included. 
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Figure 8. Arbitrary orientation tensors centered in the center of mass of the C-terminal 
domain, color-coded with respect to the difference in MO values upon inclusion of pcs and 
rdc of Tm3+-ClaNP-5 CaM. The colors change from blue (difference in MO of 0.1) to red 
(difference in MO of 0.25) for the structures with MO differences larger than 0.1.  
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Supporting Information 
S1: MO calculation 
The MO (maximum occurrence) values for hundreds of conformations of CaM have 
been computed using the paramagnetic restraints pcs and rdc obtained from metal ions 
positioned in two different metal binding sites located in protein domains which are mobile 
with respect to the one another. The calculations for the different conformations were 
performed simultaneously on a grid system. 
A subroutine was implemented into the MO program to calculate the contribution to 
the target function (TF) arising from violations in the pcs and rdc values of nuclei located in 
the moving domain with respect to the reference frame fixed on the metal containing 
domain. Starting from a reference protein conformation, the relative orientation of the C-
terminal domain with respect to the reference frame fixed on the N-terminal domain was 
calculated as a clockwise rotation; the opposite (anticlockwise) rotation was applied to 
determine the inter-domain orientation when the reference frame is fixed on the C-terminal 
domain. Similarly, a translation with the same amplitude but in the opposite direction was 
performed to compute the relative position of the domains.  
In the present study, when the metal ion is coordinated to the N-terminal domain, the 
different conformations of CaM are obtained by moving the C-terminal domain from a 
position P(x,y,z) to a new position P’ through a rotation R and a translation t. The new 
position P’ of the C-terminal domain was computed as R*(P-t). On the other hand, when the 
metal ion is fixed to the C-terminal domain, the same conformation of CaM is obtained by 
moving the N-terminal domain to the corresponding relative position P’ computed as (R-
1*P) +t. The R rotation matrix was obtained from the Euler angles in the ZYZ convention: 
                                  














22323
123123112331
211313231321
csssc
sssscccsccsc
scsccscssccc
R                [S1] 
where c and s mean cosine and sine, and the subscripted numbers 1,2,3 indicate the three 
Euler angles (P,O,T). 
The protocol used to calculate the MO values was the following: 
1. A set of 400 fixed conformations representing the conformational space sampled by 
CaM was generated using the program RANCH (1). The following calculations were 
then performed for each conformation. 
2.  A weight smaller than 100% was fixed for the selected conformation. Other 
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conformations with different weights (the sum of all weights being constrained to 1) 
were then added one by one, and each time a simulated annealing minimization was 
performed, in order to obtain the best possible agreement with the experimental data. A 
maximum number of 15 conformations was used to best fit the experimental 
observables. The TF to be minimized was defined as 
                               21000),,(,0 ),(),(
~min)(
0
  
j
N
i iijijjRtwt
RtwRtwwTF
iii
             [S2] 
where j
~ are the experimental pcs/rdc values, ),( 00 Rtj are the pcs/rdc values calculated 
for the selected conformation with orientation 0R  and translation vector 0t , 0w is the 
corresponding weight, and ),( iij Rt are the pcs/rdc values calculated for the other 
i=1…N conformations with weight wi, position ti, and orientation Ri. During the  
minimization, conformations with weight less than 10-3 were removed, in order to ensure 
convergence more rapidly. 
3.  The weight of the selected conformation was changed and step 2 was repeated (using the 
ensembles calculated with different weights as starting points for the minimization). 
4. The MO of each selected conformation was calculated as the weight at which the TF is 
10% larger than the minimum value achieved at low weights.  
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Figure S1.1 Flow chart of MO calculations 
 
 
 
 
S2: Synthetic tests 
A simulation was performed by generating a family of 50000 conformations with a 
Gaussian distribution around one selected conformation, shown in Fig. S2.1, corresponding 
to the PDB 1CLL conformation. The orientation of the C-terminal domain with respect to 
that of the N-terminal domain of any conformation of the family is defined by 3 Euler 
angles. Pcs and rdc data corresponding to metals (with their anisotropy tensors) positioned 
in either the N or the C-terminal domains were then calculated according to the generated 
family of conformations. 
Calculations were then performed using different sets of pcs and rdc data to check 
the sensitivity of MO to the different probability of the conformations within the family. The 
MO values of the conformation at the centre of the Gaussian distribution and of other 8 
conformations defined by changing each of the 3 Euler angles of ±50° (standard deviation of 
the distribution) from the central conformation were calculated. 
A signal to noise is defined as the ratio between the MO of the conformation at the Gaussian 
centre and the average of the MO values of the other 8 conformations:  
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A larger signal to noise indicates an increased capability of the MO values to 
discriminate the conformations with larger probability from those with smaller probability. 
One of the 8 conformations was actually excluded in the performed calculations because in 
such conformation the two domains crashed.  
The calculations were performed both without and with including an experimental 
error on the simulated pcs and rdc data, using a total of 4 or 5 metal ions with different 
anisotropy tensors. Without errors, the signal to noise ratio was almost the same (1.26), 
irrespective of the distribution of the lanthanides within the two domains, if only rdc data are 
used in the fit. A small difference in the signal to noise ratio was observed when a Gaussian 
error was added to the rdc data. The best signal to noise ratio of 1.36 was obtained in the 
case of 3 metals in the N-terminal domain and 2 metals in the C-terminal domain (3+2 case) 
relative to the other distributions of the metal ions in the two domains (see Table S2.1).  
The same analysis was performed including the pcs data into the calculations. MO 
values were obtained for the central and the other 7 conformations using pcs and rdc data 
without error (Fig.S2.2) and with error (pcs’ and rdc’) (Fig.S2.3). The pcs’ and rdc’ values 
are defined as: 
                                    01.0)01.01(' 21  YgYgpcspcs                               [4] 
                                    1.0)1.01(' 21  YgYgrdcrdc                                    [5] 
                                    )sin()log(2 211 XgXgYg                                     [6] 
                                    )cos()log(2 432 XgXgYg                                   [7] 
where Xg1, Xg2, Xg3 and Xg4 are four random numbers (from 0 to 1). 
Table S2.1 reports the signal to noise ratio obtained from simulated data calculated 
with 4 or 5 metal ions differently distributed in the two protein domains. Both with and 
without inclusion of an experimental error, the presence of metals in different domains is 
definitely advantageous. The signal to noise ratios in the cases of 3+1 and 2+2 metal 
distributions (number of metals in N-terminal + C-terminal domains) are always higher than 
in the 4+0 case.  
 
 
Signal 
Noise 
MAP of conformation at Gaussian centre  
Average MAP of the other 8 conformations = [3] 
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       Table S2.1 Signal to noise ratio for the performed simulations 
Signal to noise ratio Metals 
in N-
terminal 
+ C-
terminal 
domains 
 
Rdc restraints 
(no error) 
Rdc 
restraints 
(with error) 
rdc+pcs 
restraints 
(no error) 
rdc+pcs 
restraints 
(with error) 
4+0 1.24 1.23 1.28 1.35 
3+1 1.26 1.33 1.37 1.43 
2+2 1.25 1.20 1.54 1.42 
5+0 1.23 1.29 1.33 1.47 
3+2 1.26 1.36 1.60 1.51 
 
 References 
(1) Bernadó P, Mylonas E, Petoukhov MV, Blackledge M, Svergun DI. (2007), J Am Chem 
Soc, 129: 5656-64. 
Fig. S2.1 Gaussian distribution of the conformational family (magenta) around one selected 
conformation (yellow) 
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Fig. S2.2. MO analysis of the selected conformations within the simulated Gaussian 
distribution. Pcs and rdc data are simulated without including errors.  
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Fig. S2.3. MO analysis of the eight selected conformations within the simulated Gaussian 
distribution . Pcs and rdc data are simulated with addition of a Gaussian error.  
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S3: Best fit graphs 
Correlation between rdc (A) and pcs (B) values measured for nuclei belonging to the domain 
without the lanthanide ion and rdc and pcs values calculated from the ensemble of 
conformations providing a minimum value of TF in the MO calculations 
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S4. Figure S4. 1H-15N HSQC spectra of Lu3+-CLaNP-5 H107C/N111C CaM (red) and of 
N60D Ca4CaM (black). Moving peaks are those around the mutation sites, i.e. around 
residues 60, 107, 111 or belonging to residues close in space to the mutation site (i.e. T26, 
I27 close to N60). 
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S5. Experimental restraints 
RDC of N60D CaM  RDC of CLaNP-5-CaM 
  Residue Tb Tm  Dy    Residue Yb Tm 
4 LEU - - -0.142  7 GLU - 1.348 
5 THR -18.447 0.098611 -17.808  16 PHE - 1.135 
6 GLU 6.953 1.064 4.683  21 LYS+ - 0.780 
7 GLU 3.335 - 7.024  22 ASP - 0.000 
9 ILE 5.818 2.483 3.264  23 GLY - 0.000 
10 ALA 8.585 -7.450 -9.153  24 ASP - 0.709 
11 GLU 2.199 - -  25 GLY - -2.058 
12 PHE -3.335 -1.419 -5.605  26 THR - -1.987 
13 LYS+ 16.177 - 12.984  28 THR - -2.129 
14 GLU 5.818 - -  29 THR - -0.780 
15 ALA - -3.831 9.011  30 LYS+ - -0.071 
16 PHE - - 9.862  32 LEU - -0.497 
17 SER 15.254 - -  33 GLY - 0.851 
18 LEU - -5.534 -  35 VAL - -0.993 
19 PHE -0.851 -2.341 -  38 SER - -0.639 
22 ASP - -9.862 -  40 GLY - 1.348 
23 GLY -14.048 11.565 -2.909  42 ASN - 0.780 
24 ASP - 7.946 -16.319  45 GLU - 0.780 
29 THR - -1.561 -0.922  46 ALA - -0.071 
30 LYS+ 2.767 - -  48 LEU - -0.071 
31 GLU 2.554 12.629 -  49 GLN - 0.355 
32 LEU 2.554 - -  50 ASP - 0.142 
33 GLY 3.477 9.294 -  52 ILE - 2.696 
34 THR - 10.572 -1.206  53 ASN - 0.851 
35 VAL - 11.281 -  56 ASP - -0.922 
36 MET - 7.450 -2.483  57 ALA - -0.071 
37 ARG+ -17.241 - -11.281  58 ASP - -1.490 
38 SER -10.430 - -20.292  59 GLY - -1.632 
39 LEU -10.501 - -  60 ASP - 1.490 
40 GLY -9.153 4.115 4.044  62 THR - -0.568 
41 GLN -14.261   4.825  63 ILE - -1.774 
44 THR - -1.774 1.490  64 ASP - -0.497 
45 GLU - -1.845 -  65 PHE - -0.071 
47 GLU -24.407 - -  85 ILE -3.193 19.866 
48 LEU - -0.993 -7.734  86 ARG+ 2.980 3.193 
49 GLN - 1.135    87 GLU 3.264 21.994 
50 ASP - 8.656 1.490  88 ALA 3.831 22.562 
84 GLU - - -0.639  89 PHE 3.831 22.562 
85 ILE - 0.497 -0.639  90 ARG+ 2.767 11.068 
86 ARG+ - - -0.851  91 VAL 2.625 -14.758 
89 PHE - 1.490 -0.710  92 PHE 2.412 21.143 
90 ARG+ - 1.206 -1.206  93 ASP 2.838 21.569 
91 VAL -0.426 - 0.284  94 LYS+ -1.561 -5.037 
93 ASP -2.412 2.058 -1.277  95 ASP 3.477 21.853 
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94 LYS+ -0.284 0.568 -1.206  96 GLY -2.270 -13.126 
95 ASP 1.490 0.000 0.993  97 ASN -3.902 -1.703 
96 GLY - -0.497 0.142  98 GLY -2.483 4.683 
97 ASN -1.206 0.213 -1.490  99 TYR 4.257 0.142 
98 GLY 1.774 -0.497 1.490  100 ILE 4.896 23.839 
99 TYR 0.993 -0.780 1.916  101 SER 7.024 9.011 
100 ILE 1.277 -0.780 1.064  102 ALA -1.987 -6.953 
101 SER 1.845 -0.497 1.348  103 ALA -5.037 19.937 
102 ALA 0.426 -0.710 0.142  104 GLU 0.497 - 
103 ALA 0.284 0.000 0.568  105 LEU -2.341 0.497 
105 LEU 0.851 -0.568 0.071  112 LEU 3.548 - 
106 ARG+ 0.000 0.568 0.568  113 GLY -1.561 20.859 
107 HIS+ - - 0.568  114 GLU 3.547 - 
109 MET 0.497 - -  115 LYS+ 3.264 2.129 
110 THR 0.568 - -0.142  116 LEU 9.436 23.626 
111 ASN 0.213 0.000 -  117 THR -6.669 18.589 
112 LEU - - 0.851  118 ASP 1.703 21.924 
113 GLY - - -0.213  119 GLU 0.710 -6.527 
114 GLU -0.213 - -0.568  120 GLU 3.547 - 
115 LYS+ 0.142 0.284 -0.355  121 VAL -2.838 20.717 
116 LEU 0.426 0.000 -0.709  122 ASP -1.206 21.782 
117 THR 1.774 -0.851 1.703  123 GLU 3.335 22.065 
118 ASP -1.064 0.426 -0.426  124 MET 3.547 - 
119 GLU -0.993 -0.497 0.071  125 ILE 2.483 21.214 
121 VAL - -0.071 -0.426  126 ARG+ -0.142 - 
122 ASP -1.135 0.000 -0.568  127 GLU 2.412 5.676 
123 GLU - -0.780 -0.497  128 ALA 2.483 21.214 
124 MET 0.213 -0.993 0.640  129 ASP 3.264 -17.808 
127 GLU 0.426 -1.135 1.348  130 ILE 1.206 3.264 
128 ALA - 0.071 -  131 ASP 2.483 27.529 
129 ASP -1.916 0.213 -1.206  132 GLY -0.213 -5.889 
130 ILE 0.000 0.284 -0.568  133 ASP -4.186 -11.849 
131 ASP 1.490 -0.922 1.206  134 GLY 1.064 12.345 
132 GLY -0.284 -0.071 -0.497  135 GLN 2.696 12.487 
134 GLY 0.710 -0.213 0.922  136 VAL 4.328 20.008 
135 GLN 0.851 -0.993 1.703  137 ASN 3.193 26.819 
136 VAL 1.419 -0.851 1.774  138 TYR 8.656 21.64 
137 ASN 1.561 - 1.561  139 GLU 0.355 -11.636 
138 TYR 0.142 - -  140 GLU 1.064 22.562 
140 GLU 0.568 0.284 -0.071  141 PHE 0.568 -9.082 
141 PHE 0.922 -0.071 0.000  142 VAL -2.341 21.498 
142 VAL 0.639 -0.284 -0.213  143 GLN 3.547 - 
143 GLN 0.284 0.213 -0.426  144 MET 1.987 3.831 
144 MET 0.142 - -  145 MET -2.270 -16.744 
145 MET 0.568 -0.710 -0.709      
147 ALA -0.426 0.142 -0.071      
148 LYS+ - -0.568 -0.213      
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PCS of N60D CaM  PCS of CLaNP-5-CaM 
  Residue Tb Tm  Dy    Residue Yb Tm 
4 LEU -0.039 - 1.629  6 GLU -0.029 -0.006 
5 THR 1.074 -0.589 1.146  7 GLU -0.033 - 
6 GLU 1.184 -0.609 1.095  10 ALA - 0.019 
7 GLU 1.092 - 0.966  13 LYS+ -0.003 - 
8 GLN - - 0.771  15 ALA -0.023 - 
9 ILE 1.750 -0.967 1.564  16 PHE - -0.011 
10 ALA 1.870 -1.062 1.66  18 LEU -0.020 -0.065 
11 GLU 1.426 - -  19 PHE -0.021 - 
12 PHE 1.749 -1.006 1.29  21 LYS+ -0.002 -0.040 
13 LYS+ 2.751 - 1.87  22 ASP -0.010 -0.027 
14 GLU 1.886 - 1.008  23 GLY -0.014 - 
15 ALA 2.352 -0.748 0.229  24 ASP -0.017 -0.048 
16 PHE - - 0.317  25 GLY - -0.044 
17 SER 2.031 - -  26 THR -0.012 -0.042 
18 LEU 0.009 -0.544 -  27 ILE -0.022 - 
19 PHE 0.116 -0.054 -  28 THR - -0.058 
21 LYS+ -1.338 - -2.043  29 THR -0.018 - 
22 ASP -0.685 -0.821 -  30 LYS+ -0.003 -0.024 
23 GLY 0.644 -1.491 -1.159  31 GLU -0.014 -0.056 
24 ASP 1.148 -2.372 -1.529  33 GLY -0.029 -0.085 
29 THR - -0.016 -0.027  35 VAL - -0.068 
30 LYS+ -4.582 - -  38 SER -0.011 - 
31 GLU -5.190 1.041 -  44 THR -0.025 -0.127 
32 LEU -7.254 - -  45 GLU -0.007 - 
33 GLY -4.681 2.837 -  46 ALA -0.003 -0.020 
34 THR -4.999 1.698 -2.129  48 LEU -0.007 -0.076 
35 VAL -1.719 1.743 -  49 GLN -0.018 - 
36 MET -2.440 2.032 -2.63  50 ASP -0.023 -0.037 
37 ARG+ -2.037 - -1.406  51 MET - -0.011 
38 SER -1.652 - -1.455  52 ILE -0.022 - 
39 LEU -1.392 - -  53 ASN -0.004 -0.011 
40 GLY -1.182 0.798 -1.489  54 GLU - 0.001 
41 GLN -1.344 - -1.655  55 VAL -0.032 - 
42 ASN -2.073 - -  56 ASP - -0.037 
44 THR -0.949 1.217 -0.946  57 ALA -0.016 -0.023 
45 GLU - 0.845 -  58 ASP -0.012 -0.010 
47 GLU -1.364 - -  59 GLY 0.010 0.014 
48 LEU - 2.231 -1.195  60 ASN -0.001 0.000 
49 GLN - 2.365 -  61 GLY -0.027 - 
50 ASP -2.379 2.435 -0.016  62 THR - -0.011 
84 GLU - - 0.012  64 ASP -0.028 -0.085 
85 ILE - 0.124 -  65 PHE -0.009 - 
86 ARG+ - - 0.013  68 PHE -0.014 - 
89 PHE -0.095 0.070 0.002  70 THR -0.029 - 
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90 ARG+ - 0.078 0.035  86 ARG+ - 0.715 
91 VAL -0.134 0.007 0.064  90 ARG+ - 0.904 
93 ASP -0.115 - 0.024  91 VAL - 1.511 
94 LYS+ -0.088 0.044 -  93 ASP 0.523 - 
95 ASP -0.061 0.029 0.043  94 LYS+ 0.503 1.504 
96 GLY -0.062 0.027 0.040  95 ASP -0.140 - 
97 ASN -0.056 0.037 0.027  96 GLY -0.268 - 
98 GLY -0.080 0.036 0.013  97 ASN -0.071 -0.797 
99 TYR -0.064 0.047 0.017  98 GLY -0.066 -0.274 
100 ILE -0.095 0.056 0.009  99 TYR 0.148 0.649 
101 SER -0.080 0.049 0.011  100 ILE 0.503 2.73 
102 ALA -0.066 0.048 0.002  101 SER 0.702 3.137 
103 ALA -0.070 0.043 0.000  102 ALA 0.561 2.26 
104 GLU -0.035 0.048 0.007  103 ALA 0.645 - 
105 LEU -0.105 0.064 -0.004  104 GLU 1.118 3.867 
106 ARG+ - 0.057 -0.026  105 LEU 1.467 - 
107 HIS+ - - -0.021  113 GLY 1.565 - 
109 MET -0.115 - -0.055  115 LYS+ - 3.184 
110 THR -0.010 0.008 -  116 LEU 0.654 - 
111 ASN -0.002 0.000 0.000  117 THR 0.337 2.02 
112 LEU - - -0.041  118 ASP 0.250 - 
113 GLY -0.011 0.013 -0.011  121 VAL 0.546 - 
114 GLU - - -0.010  122 ASP - 1.812 
115 LYS+ -0.002 0.017 0.001  123 GLU 0.364 - 
116 LEU -0.017 0.000 -0.068  124 MET - 2.345 
117 THR -0.102 0.074 -0.059  127 GLU 0.295 - 
118 ASP -0.078 0.058 -0.045  128 ALA 0.430 - 
119 GLU -0.065 0.061 -0.027  129 ASP - 1.927 
121 VAL - 0.057 -0.040  130 ILE 0.253 1.139 
122 ASP -0.057 0.058 -0.017  131 ASP 0.184 - 
123 GLU 0.017 0.051 -0.021  132 GLY 0.179 1.069 
124 MET -0.018 0.057 -0.023  133 ASP 0.179 - 
127 GLU -0.097 0.031 -0.029  134 GLY 0.214 1.264 
128 ALA -0.087 0.054 -0.008  135 GLN - 1.324 
129 ASP -0.072 - 0.005  136 VAL 0.500 2.77 
130 ILE -0.090 0.042 -0.010  137 ASN 0.298 1.73 
131 ASP -0.078 0.036 -0.010  138 TYR 0.157 - 
132 GLY -0.048 0.050 -0.002  139 GLU 0.142 0.936 
133 ASP -0.043 - -  140 GLU 0.222 1.389 
134 GLY -0.065 0.031 -0.005  141 PHE 0.340 2.057 
135 GLN -0.065 0.039 -0.003  142 VAL 0.260 1.67 
136 VAL -0.085 0.051 -0.001  143 GLN - 1.414 
137 ASN -0.096 0.057 -0.002  144 MET 0.351 1.833 
138 TYR -0.109 0.050 -0.010  145 MET 0.402 2.552 
139 GLU -0.080 - -      
140 GLU -0.118 0.069 0.001      
141 PHE -0.130 0.071 -0.003      
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142 VAL -0.152 0.080 0.003      
143 GLN -0.143 0.081 0.000      
144 MET -0.037 - -      
145 MET -0.163 0.080 -0.006      
147 ALA -0.151 0.107 0.021      
148 LYS+ -0.147 0.087 0.017      
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4.   Conclusions  
The solution structure of S100A5 was determined for apo and Ca2+ forms by NMR 
spectroscopy. Both forms are homodimeric in solution. The overall structures of apo and 
Ca2+ S100A5 are in good agreement with those obtained for other S100 proteins such as 
S100A1, S100A4, S100A6, S100A8, S100A12, S100B. Comparison of the apo and calcium-
loaded structures shows that the N-terminal EF-hands are similar to one another, indicating 
there is no large conformational rearrangement in this region upon calcium binding. In 
contrast, the C-terminal EF-hand undergoes a major conformational change upon calcium 
binding. This rearrangement includes a considerably different orientation of helix III and 
non-negligible changes in helix IV and the hinge loop. These rearrangements upon calcium 
binding are similar to those observed for other S100 proteins with the exception of S100A10 
which has a ‘calcium ready state’ in N-and C-terminal EF-hands although it does not bind 
calcium. In S100A5, the angles between helices III and IV changes from 168° to 118° on 
passing from the apo to calcium form. The structural changes induced by Ca2+ binding to the 
dimer leads to the exposure of two symmetrically positioned clefts defined by helix III, helix 
IV, the hinge loop and the last C-terminal residues, in a way similar to that found in other 
S100 proteins, where target proteins can be accommodated. These changes are important as 
they must be related to the functions of this protein which are still unknown. For the first 
time, relaxation measurements were performed on apo and calcium forms of a S100 protein. 
A large mobility was observed in the hinge loop which is not quenched in the calcium form. 
The structural changes induced upon calcium binding were found to change the global shape 
and distribution of hydrophobic and charged residues of the S100A5 dimer in a modest but 
significantly different manner with respect to the closest homologues S100A4 and S100A6. 
Despite sharing a very high degree of structural homology, S100 proteins exhibit 
diverse functional roles. Several S100 proteins are secreted into the extracellular space. 
They exert their cellular effect through activation of the cell surface receptor, RAGE. 
However, the mechanism of activation varies among the different S100 proteins. Therefore, 
S100-RAGE interaction was investigated using a set of 7 recombinant S100 proteins (some 
reported to be extracellular and others not reported). Studies were based on cell line and 
NMR experiments. It was found that all these S100 proteins activate RAGE by increasing 
cell proliferation but with different potencies. For each protein, the concentration with 
maximal effect on cell proliferation was determined. S100A4 and S100A5 were found to 
have optimal influence on cell proliferation at a concentration 10 times lower compared to 
the other S100 proteins. NMR experiments revealed that no all S100 proteins bind to the 
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same extracellular domain of RAGE. S100A12 binds to the C1C2 domain while others bind 
to the V-domain. These findings were further verified through competition experiments in 
cell lines where cells were treated with S100 proteins in the presence of different constructs 
of extracellular RAGE, V, VC1 and C1C2. The RAGE domain which binds to each S100 
protein, thereby preventing activation of the receptor on the cells and hence cell proliferation 
was determined. Our results from cell lines were consistent with NMR experiments for all 
the S100 proteins studied. The interaction of S100P with RAGE was investigated in detail 
and a model was proposed of the complex base on chemical shift perturbations. A dimer of 
S100P was found to interact with a monomer of VC1-RAGE. For the first time, a study was 
conducted on 7 different S100 proteins under the same conditions to avoid discrepancies 
arising from previous studies. Our studies also shed light on the possible biological function 
of S100A5. Although this protein is not reported to be extracellular, it was found to interact 
with the V-domain of RAGE in a manner comparable to other S100 proteins which are 
known to be secreted into the extracellular space. Thereby, our finding provides a hint for 
the extracellular role of S100A5 whose functional significance is yet to be explored. 
Moreover, the fact that S100-RAGE interactions promote cell proliferation suggests their 
role in tumour development. Hence these complexes can be significant drug targets. 
Till now the probable spatial conformations of the two-domain protein CaM were 
studied with paramagnetic ions in the N-domain, i.e. N-domain as fixed and the C-domain 
as moving. Studies were performed using a paramagnetic probe at the C-domain, whereby 
the N-domain is moving. Combined analysis of these two sets of data show that the 
simultaneous use of paramagnetic restraints arising from lanthanide ions located in different 
domains of proteins experiencing interdomain mobility is quite informative for the 
determination of the maximum occurrence of any conformation. The information obtained 
from paramagnetic ions located in different domains of a protein is more than that obtained 
by placing the same number of metal ions in the same site mostly due to differences in 
orientations of the magnetic susceptibility anisotropy tensors. In case of CaM, we have 
shown that the maximum occurrence of several conformations is considerably reduced by 
the addition of pcs and rdc arising from a single metal ion rigidly attached to the C-terminal 
domain in comparison with the values obtained with three metal ions placed in the N-
terminal domain of the protein. As a result, the probable conformations experienced by the 
protein can be more accurately mapped.  The significance of this study also lies in the broad 
applicability of the methodology. It can serve as a general approach to study any multi- 
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domain protein or two interacting protein partners where there is mobility between the 
domains or the partners. 
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